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List of abbreviations
AR Accelerated Radiotherapy
ARCON Accelerated Radiotherapy combined with Carbogen breathing and Nicotinamide
ATP Adenosinetrifosfaat
CAIX carbonic anhydrase IX
CT computed tomography
DAB diaminobenzidine
DFS disease-free survival
EF-5 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide
EGFR epidermal growth factor receptor
EMT epithelial-mesenchymal transition
GLUT-1/-3 glucose transporter-1/-3
Gy Gray [J×kg-1]
h hour
Hb hemoglobin
HE haematoxylin-eosin staining
HIF-1 hypoxia-inducible factor-1
HNSCC head and neck squamous cell carcinoma
HPV human papillomavirus
IdUrd iododeoxyuridine 
Ki-67 endogenous proliferation marker
LC local control
LDH-5 lactatedehydrogenase-5
LI labeling index
MCT1/4 monocarboxylate transporter 1/4
MFS metastasis-free survival
MRI magnetic resonance imaging
M-stage distant metastasis
N-stage regional lymph node metastasis
OS overall survival
PAD primary antibody diluent
PBS phosphate buffered saline
PI3-K phosphatidyl-inositol-3’ kinase
pimonidazole 1-([2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride 
pO2 oxygen partial pressure
RC regional control
RVA relative vascular area
TNM classification of malignant tumors 
TPZ tirapazamine
T-stage extent of primary tumor
VD vascular density
VEGF vascular endothelial growth factor
VHL Von Hippel-Lindau
WHO World Health Organization
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Laryngeal carcinoma
Every year around 700 cases of laryngeal cancer are diagnosed in the Netherlands.1 The 
disease is more prevalent in males than females with a factor 7:1, although incidence is 
increasing in females.2 This is probably due to the changing smoking habits in the past 
decades, smoking being the most important etiological factor for larynx carcinoma. Other 
etiological factors include alcohol use3 and to a lesser extent occupational exposures4 and 
human papilloma virus (HPV)5.
 Squamous cell carcinoma is by far the most prevalent histopathological diagnosis, 
other histologies are rare. Two third of the laryngeal cancers is located supraglottic, about 
one third glottic and subglottic localisation is very rare (about 2% of cases).6 The anatomy 
of the larynx illustrating the different subsites is shown in Figure 1.
The treatment for the early stages comprises laser surgery or radiotherapy with excellent 
long term results.7 In the more advanced stages, it is still a challenge to achieve long term 
local control and survival. The last decades a shift in therapy has occurred for these 
tumours from laryngectomy to radiotherapy to preserve organ function, with a similar 
patient outcome for both modalities.8 Still a significant subset of patients is faced in time 
with locoregional recurrence or distant metastases. Hypoxia (the lack of oxygen) is an 
important resistance mechanism that can cause therapy failure. 
Fig. 1  Anatomy of the larynx.
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Pathophysiology of hypoxia
In most malignant tumours there is an imbalance between the supply and consumption 
of oxygen, leading to hypoxic and even anoxic regions. During the rapid growth of a 
tumour an aberrant, chaotic microvasculature develops. Tumours exhibit a vascular 
network with a wide range of vessel diameters, intervascular distances and interbranching 
distances unlike those seen in normal tissue.21 The morphological and functional 
deformed blood vessels diminish the oxygen delivery to the tumour cells, resulting in a 
low oxygen microenvironment. Another factor contributing to a decrease in oxygen 
supply is tumour-associated and therapy-induced anaemia, leading to a diminished 
oxygen transport capacity of the blood (anaemic hypoxia).22
 From a pathophysiological point of view hypoxia can be divided into acute, or 
perfusion-limited hypoxia and chronic, or diffusion-limited hypoxia, although this division 
is arbitrary.23 Acute hypoxia is often transient and is caused by a temporary disruption in 
blood flow as a result of an occlusion or rise in interstitial fluid pressure. In xenografts only 
a small part of the tumour hypoxia is of the intermittent type.24 
 Chronic hypoxia arises with an increased distance of tumour cells from the 
microvessels (> 70 µm) in the distorted architecture of the vascular network. Acute and 
chronic hypoxia combine in a heterogeneous pattern throughout the tumour so that 
severe, intermediate and low levels of hypoxia can be identified. From a clinical standpoint 
it has been proposed that the intermediate and transient hypoxic cells are the most 
important for prognosis.25 These cells are (temporarily) resistant to therapy and still have 
the ability to proliferate.26
 Because the degree of hypoxia is extremely variable on a continuous scale, a strict 
cut-off value to discriminate normoxic from hypoxic cells does not exist. Critical metabolic 
processes fail at different pO2-levels (Figure 2). A median O2 partial pressure of less than 10 
mm Hg already results in ATP depletion. The oxidative phosphorylation gradually declines 
below this value till it ceases at O2 partial pressures of less than 0.5 mm Hg. Radioresistance 
may already occur below 25-30 mm Hg.27 In most experiments, values from 0.5 mm Hg to 
10 mm Hg have been used as a cut-off value to discriminate normoxic from hypoxic 
tumour cells.
Tumor metabolism
Malignant tumors often exhibit an altered metabolism compared to normal tissues. This 
phenomenon can be explained by several underlying mechanisms. First of all, the genetic 
changes related to a high proliferation rate, as observed in many tumors, lead to an 
increased metabolism.28 Another important reason for a changed metabolism is the 
adaptation of tumor cells to the microenvironment. Under circumstances of severe 
hypoxia, cells are forced to use anaerobic glycolysis as their primary energy source, the 
Pasteur effect (Figure 2).29 Normal cells convert to oxidative phosphorylation when oxygen 
levels are restored. In contrast, tumor cells can use glycolysis even in the presence of 
Radiotherapy and the oxygen effect
The effect of radiotherapy on tumor cells is strongly dependent on the presence or 
absence of oxygen, the so called oxygen-effect.9 Under hypoxic circumstances, a higher 
radiation dose is needed to cause the same biological effect. This relationship is described 
by the oxygen enhancement ratio (OER) and is defined by the radiation dose in hypoxia 
divided by the radiation dose in air. The enhancement of radiation damage by oxygen is 
explained by the fixation of DNA damage by oxygen. Radiation causes highly reactive free 
radicals in the DNA of the tumor cell, either direct or indirect. These free radicals rapidly 
react with oxygen which eventually causes a stable chemical fixation of the DNA damage. 
In the absence of oxygen the free radicals have more time to restore their original form.
Hypoxia and the tumor microenvironment
The tumour microenvironment is of great importance, influencing malignant cells in 
various ways.10 Within this microenvironment, hypoxia is an extensively studied parameter, 
with relevance in almost all types of solid tumours. As early as 1936 Mottram mentions the 
relative insensitivity of mammalian cells under anaerobic conditions.11 Gray described in 
1953 the presence of hypoxia in murine tumour cells and the associated reduced sensitivity 
to radiotherapy.12 Hypoxia has negative implications for clinical outcome. This is probably 
based on two distinct principles: hypoxic cells are more resistant to radiotherapy and 
chemotherapy, and they give rise to genetic instability and more aggressive phenotypes. 
 Especially the increased resistance to radiotherapy is a well-known phenomenon 
associated with tumour hypoxia, most studied in head and neck cancer and cervical 
carcinoma.13,14  Besides this increased resistance to radiotherapy, there is evidence that 
hypoxic cells are responsible for decreased sensitivity to certain chemotherapeutic agents 
as well, such as doxorubicin, 5-fluorouracil and methotrexate. These data are mainly 
derived from animal and in vitro studies.15-17  There is scarce recent literature available on 
this subject.
 Besides this resistance to chemo- and radiotherapy, surgically treated soft-tissue 
sarcomas and cervical carcinomas also exhibit hypoxia as a prognostic factor for poor 
survival.13,18  A correlation was found between the rate of distant metastases and tumour 
oxygenation in soft tissue sarcoma.19  Furthermore, in cervical cancer it has been proven 
that hypoxic tumours exhibit more frequent parametrial spread and lymph-vascular space 
involvement.13 A subgroup of hypoxic tumours with diminished apoptotic potential 
showed increased lymphatic spread and higher probability of recurrence as well.20 These 
findings indicate that hypoxia stimulates tumour cells to develop towards a more invasive 
phenotype and can be regarded as a sign of tumour aggressiveness.
Fig 1. Anatomy of the larynx 
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numerous studies, with the main focus on breast cancer.37 Several studies assessed the 
prognostic value of Ki-67 in laryngeal cancer specifically, but most in surgically treated patients. 
Some of those have shown a correlation of Ki-67 labeling index with recurrence or disease- 
free survival, but none of them have established a correlation with overall survival.36 
 Although a direct relationship between hypoxia and proliferation has never been 
found, in theory there is a mutual relationship between proliferation and hypoxia. Highly 
proliferating tumours with rapid growth will easily give rise to hypoxic areas. Furthermore, 
hypoxic conditions can drive a cell towards a more aggressive phenotype with higher 
proliferation rate and more regional and distant metastasis.38 
 Hypoxic cells that have retained their proliferative capacity could be the cause of 
persistent or recurrent disease. A previous study showed the presence of such a subgroup 
and its correlation with disease-free survival.26
Measuring hypoxia
Over the years different methods have been developed for assessing the level of hypoxia 
in tumours in vivo, with the polarographic oxygen electrode mostly used as the gold 
standard. However, the invasive nature of this method led to the development of other 
techniques. Nowadays, the focus has shifted to exogenous markers, like EF5 and 
pimonidazole and a wide range of hypoxia-related endogenous markers (Figure 3). The 
cellular responses to hypoxia are complex, with many different genes and proteins 
involved. Measuring hypoxia with imaging modalities such as magnetic resonance 
imaging (MRI) and positron emission tomography (PET) is another promising field of 
research, which is a subject beyond this thesis.
Polarographic needle electrode
Being regarded as the gold standard for a long time, the polarographic oxygen electrode 
has been extensively used for quantifying hypoxia in both animal studies and human 
tumours.39,40 With this invasive technique oxygen concentrations can be measured directly 
at many different positions in the tumour and within a short time frame. Although the 
Eppendorf electrode, introduced in the late 1980’s, is a vast improvement compared to 
the older systems, the method still has some major drawbacks. It is limited to accessible 
tumour sites like head and neck and cervical cancer, disrupts the tissue and it has a large 
inter-observer variability.41 Another restriction of this technique is the failure to distinguish 
necrotic areas from viable tumour tissue and to discern the patterns of hypoxia.
Exogenous markers
The limitations of the needle electrode led to the development of exogenous markers, 
the 2-nitroimidazoles, to measure hypoxia (Figure 3A and B). Two markers are approved for 
sufficient amounts of oxygen. This is called the Warburg effect, a manifestation of a 
modification of the tumor cell metabolism.30 Due to a high level of aerobic glycolysis, in 
many tumor cells, glucose consumption is substantially higher than in normal cells.31,32
 The consequence of the high rate of glycolysis in malignant cells is the production of 
large amounts of lactic acid. An interesting observation made by Sonveaux et al. is the 
preference of tumor cells for lactic acid over glucose as the primary energy source.33 This 
creates the perfect conditions for a symbiosis between anaerobic glycolytic cells and 
aerobic tumor cells33 or aerobic stromal cells, as described in colorectal carcinomas.34
Hypoxia and proliferation
In many types of cancer the pathways that regulate cell proliferation are altered and lead 
to the deregulated growth characteristic of malignant tumours. Proliferation is a well- 
known adverse prognostic factor in all types of cancer. It is correlated with differentiation 
grade, tumor size, nodal stage and DNA aneuploidy in various tumor sites and with 
hormone receptor status in breast cancer.35 In head and neck cancer high proliferation 
index is correlated with tumor characteristics and poor outcome in numerous studies.36 
This emphasizes the relationship between proliferation and tumour aggressiveness.
 There are several methods to determine the proliferation rate of tumours, that can 
measure different parameters like the growth fraction, a specific phase of the cell cycle or 
the cell cycle time.36 A widely used immunohistochemical proliferation marker that is also 
used in clinical practice is Ki-67. This endogenous marker is expressed in all phases of the 
cell cycle, with exception of the G0 phase. Ki-67 has been correlated to clinical outcome in 
Fig. 2  Cellular adaptation to hypoxia. The bars show the approximate hypoxic values below which 
cellular responses gradually change.
16 | Chapter 1 General introduction | 17
association.47 In patients with head and neck cancer treated in a phase II trial with ARCON 
(accelerated radiotherapy with carbogen and nicotinamide), a hypoxia-modifying therapy, 
pimonidazole demonstrated a predictive value as well.45
 An oral prescription of pimonidazole has become available, which remains to be 
validated.48 Recently, it has been FDA approved. For clinical use it would be a progress, 
making the administration of pimonidazole more convenient.
Endogenous hypoxia-related markers
An alternative method not relying on injected markers to quantify hypoxia is the use of 
endogenous markers, an extensive range of potential markers having been studied over 
the last years.49 Endogenous markers are proteins upregulated in association with hypoxia 
and can be measured in blood plasma or immunohistochemically on tumour biopsies, 
with the advantage that no prior infusion of markers is necessary and therefore archived 
material can be used. No single marker has consistently demonstrated strong prognostic 
power in clinical practice as of yet, although a correlation with patient outcome has been 
found for several markers. Attempts have been made to combine various markers to 
create a hypoxia-prognostic profile, with moderate success.50,51  The markers that apply to 
this thesis will be highlighted, with emphasis on their role in the hypoxic molecular 
response, the tumor metabolism and their clinical significance.
HIF-1 
Hypoxia initiates a complicated response involving a plethora of different molecular 
pathways. These pathways modulate several cellular functions, like proliferation, apoptosis, 
angiogenesis, pH balance and anaerobic glycolysis. The HIF-1 pathway with its numerous 
downstream targets is the key controller in this reaction (Figure 4).
 The transcription factor HIF-1 is a heterodimer consisting of two subunits: HIF-1α and 
HIF-1β. HIF-1β is constitutively active, while HIF-1α is rapidly degraded in normoxic 
conditions and stabilised by hypoxia.52 Upon activation HIF-1 binds to the hypoxia 
responsive element (HRE), thereby promoting the transcription of numerous genes 
including VEGF and the genes encoding for the glucose transporters. Several cofactors are 
involved in the transcriptional regulation of the various target genes.
 Under normoxic conditions two inhibitory pathways of HIF-1α are essential. Prolyl 
hydroxylases (PHD’s) hydroxylate proline sites in the oxygen-dependent degradation 
domain (ODD) of the HIF-1α protein. This enables binding of the von Hippel Lindau protein 
(VHL), which leads to the proteasomal degradation of HIF-1α. Under hypoxic conditions 
hydroxylation does not occur, leading to accumulation of HIF-1. The second main 
inhibitory pathway of HIF-1α is factor inhibiting HIF-1 (FIH-1). FIH-1 hydroxylates the 
C-terminal transactivation domain (CAD) of HIF-1α, which inhibits binding of p300/CBP to 
the HIF-1 complex, which is a co-factor necessary for transcription. Besides the oxygen-
dependent activation of HIF-1α, certain receptors of the tyrosine kinase family, like 
clinical use: pimonidazole, (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride, 
and EF5, [2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]. These 
markers can be administered intravenously and are reduced and bound to thiol-containing 
proteins in viable hypoxic cells. Pimonidazole and EF5 have been proven to be reliable 
hypoxic markers, with a good correlation with the radiobiologically hypoxic fraction42,43 
and pO2.
42,44
 Several studies have shown the prognostic value of the 2-nitroimidazoles in a clinical 
setting. In head and neck cancer a correlation was found between the degree of hypoxia 
estimated by 2-nitroimidazole binding and the locoregional control and event-free-
survival.45,46 One study performed in patients with cervical carcinoma did not show this 
Fig. 3  Photomicrographs of two human squamous-cell carcinoma xenograft cell lines (SCCNij51 
and SCCNij58) with immunofluorescent staining. The images show the differences in colocalisation 
of the exogenous marker pimonidazole (A and B) and three endogenous hypoxic markers: CAIX 
(C and D), Glut-1 (E and F) and Glut-3 (G and H) (all in green), relative to the vasculature (in red).
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in multiple ways; decreasing HIF-1α mRNA or protein levels, inhibiting DNA binding of 
HIF-1 or decreasing HIF-1-mediated transactivation.60 So far, clinical studies show limited 
success of these approaches.
Carbonic anhydrase IX
One of the downstream targets of HIF-1 is carbonic anhydrase 9 (CA9). The upregulation 
of CA9 under hypoxic conditions is controlled by the HIF-1 binding at the hypoxia 
responsive element (HRE) in its promoter region (Figure 4). This is supported by the fact 
that in VHL-defective renal cell carcinoma, in which the inhibition of HIF-1 is lost, extensive 
overexpression of CAIX can be found.61 CAIX is one of the fourteen members of the 
CA-family, existing of cytosolic, membrane-associated, mitochondrial and secreted 
carbonic anhydrases.62 CAIX (or MN, or G250) is a membrane-associated enzyme with a 
zinc-containing extra-cellular catalytic domain. This highly active domain catalyzes the 
reversible hydration of carbon dioxide to carbonic acid: H2O + CO2 ↔ H+ + HCO3-. It is 
involved in the respiratory gas exchange and acid-base balance, maintaining the 
intracellular pH and lowering the extracellular pH. CAIX can form a close interaction with 
certain ion transport systems, the so-called metabolons. The association with the 
bicarbonate transporter is recently established, affirming the role of CAIX in ion-transport 
and electrolyte-secretion.63
 CAIX is only limitedly present in normal tissue; it is found in gastric mucosa, small 
intestine and muscle. The overexpression of CAIX is demonstrated in different types of 
cancer.64 The CAIX-positive cells are mainly present in the perinecrotic areas of a tumour, 
in contrast to tumours with inactivated VHL, where a more general staining pattern is 
observed.65 The expression shows overlap with the staining pattern of pimonidazole, but 
a strong correlation is not present.45,66 There is no correlation between the amount of CAIX 
and direct oxygen measurement with the needle electrode in cervical carcinoma.67 Not-
withstanding, CAIX has proven to be a prognostic marker in various tumours, as high CAIX 
expression is associated with worse locoregional control and overall survival.62 Especially 
the combination of CAIX and a proliferation marker such as IdU or Ki67, showed 
encouraging results. These markers identify cells that are proliferating under hypoxic 
conditions, perhaps the most crucial subpopulation of tumour cells.26,68 In breast cancer, a 
quantifying assay of CAIX could identify patients who would respond least to adjuvant 
treatment, demonstrating its predictive value as well.69
 Blocking the function of CAIX, resulting in an extracellular rise in pH, can be an 
interesting approach in cancer treatment. An acid tumour microenvironment can add to 
increased chemoresistance, decreasing the uptake and consequently the cytotoxicity of 
chemotherapeutic agents and enhances metastatic potential.70 Specific inhibitors of CAIX 
have been developed, of which the sulphonamides are most promising.71 Furthermore, a 
few monoclonal antibodies to block CAIX are under investigation in renal cell carcinoma,72 
a tumour type characterised by a high CAIX-overexpression.
insulin-like growth factor receptor (IGFR), epidermal growth factor receptor (EGFR) and 
HER2/neu, can activate HIF-1α in an oxygen-independent way. They regulate the trans-
criptional activity through the P13K/Akt/mTOR pathway.53
 HIF-1α has gained interest as an endogenous hypoxia-related marker, after the 
discovery of its overexpression in a wide variety of malignant tumours.54 Its significance as 
a prognostic factor for aggressive tumour behaviour has been proven in various types of 
cancer; clear cell carcinoma, ovarian carcinoma, gastric carcinoma, breast cancer, soft-tissue 
sarcoma, bladder cancer, head and neck cancer, rectal, lung cancer and cervical 
carcinoma55, although some studies show an opposite effect.56,57  However, the correlation 
between HIF-1α expression and oxygen-electrode or pimonidazole measurements is weak.58 
Therefore, the value of HIF-1α quantification as a hypoxia assay remains questionable.
 Given the widespread overexpression of HIF-1 and its influence on multiple cellular 
functions, it is a promising therapeutic target, although the heterogeneity of the gene 
response also makes it a complex target.59 Drugs aimed at the HIF-1 pathway can intervene 
Fig. 4  Schematic representation of the HIF-1 pathway. Under normoxic conditions HIF-1α is hydroxylated 
and rapidly degraded (A). Under hypoxic conditions the HIF-1 complex is stabilised and initiates the 
transcription of its target genes. EGFR can activate HIF-1α in an oxygen-independent way (B).
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Lactate dehydrogenase
A last key protein related to the metabolism of tumor cells is lactate dehydrogenase-5 
(LDH-5), responsible for the conversion of pyruvate into lactate. LDH-5 is one of the target 
enzymes of HIF-1 and has been described to have a strong association with HIF-1α 
expression in tumor tissue sections.84,85 
Targeting hypoxia
Given the complexity of the hypoxic response, various strategies have been devised to 
target hypoxic cells. The most straightforward strategy is increasing the oxygen availability. 
Furthermore, some therapies have been developed using hypoxic cell specific toxins, 
others are aimed at decreasing their resistance to radiotherapy. Another field of research 
involves the development of drugs that target proteins involved in the hypoxic response 
or angiogenesis, but that is beyond the scope of this thesis.
ARCON (accelerated radiotherapy with carbogen and nicotinamide)
One of the first attempts to overcome hypoxia involved delivery of radiotherapy in 
hyperbaric oxygen chambers. In head and neck and cervical cancer patients treated with 
hyperbaric oxygen showed improved local tumour control and survival.86 This treatment 
was eventually abandoned as hypoxia-modifying therapy due to the complex technique 
and poor patient compliance.  
 The next step was to combine radiotherapy with normobaric oxygen or carbogen 
(98% oxygen + 2% carbon dioxide) breathing. ARCON combines accelerated radiotherapy 
with carbogen breathing and nicotinamide, a vasoactive agent, counteracting both 
diffusion-limited and perfusion-limited hypoxia (Figure 5).87 To limit clonogenic repopulation 
during therapy, the overall duration of radiotherapy is reduced by delivering multiple 
fractions per day. 
 In a phase II trial of head and neck cancer it demonstrated a substantial therapeutic 
effect in laryngeal carcinoma, notably in the more advanced tumour stages. The 3-year 
local control rate was 84% for T4 tumours, compared to around 50% in published series 
with radiotherapy alone.88 This study demonstrated not only a prognostic value but also 
the predictive potential of the pimonidazole assay. An improvement in locoregional 
control with ARCON was observed only in patients with hypoxic tumours as assessed by 
pimonidazole staining.
 In 2001 a phase III randomized trial was initiated in patients with advanced laryngeal cancer.
 The first results demonstrate that ARCON results in a high level of compliance and a 
toxicity profile, comparable to what is encountered after accelerated radiotherapy alone.89 
 Bladder cancer is the second tumour site in which the combination of radiotherapy 
with carbogen breathing and nicotinamide (CON) has shown a beneficial effect. A phase 
Fig 5. The concept of ARCON therapy
Glucose transporters
Another group of genes that is upregulated in hypoxic conditions is that of genes 
encoding for the glucose transporters (GLUTs). These transmembrane glycoproteins are 
omnipresent in normal tissue, facilitating glucose transport across the cell membrane. 
Malignant tumours generally have a higher rate of metabolism, are more dependent on 
glycolysis as an energy source (Warburg effect) and therefore have a higher glucose need. 
Under hypoxic conditions the cell’s demand for glucose increases as the anaerobic 
glycolysis becomes even more important. This also involves recruitment and 
overexpression of the glucose transporters in many malignant (hypoxic) tumours. The 
two glucose transporters most associated with invasive cancer are GLUT-1 and GLUT-3, 
being overexpressed in cervical carcinoma, head and neck cancer, colorectal and bladder 
cancer.73 A third participant has been discovered more recently in breast and prostate 
cancer: GLUT-12.74
 GLUT-1 as an endogenous hypoxia-related marker has been validated by Eppendorf 
histography, albeit with a weak correlation. Moreover, the comparison of immunohisto-
chemical staining on biopsies of cervical carcinoma of GLUT-1 and pimonidazole showed 
similar staining patterns.75 Several studies have assessed the applicability of the glucose 
transporters as prognostic markers. In cervical carcinoma high GLUT-1 expression has 
been associated with lower metastasis-free-survival76, although in another study this 
correlation was not overtly present.77 Additionally, in invasive bladder cancer, high GLUT-1 
expression has been shown to be associated with poor survival.78 GLUT-1 and GLUT-3 have 
been proposed as prognostic factors in head and neck cancer, but with equivocal 
conclusions.79-81 Summarizing, GLUT expression has some prognostic potential in solid 
tumours, but it is not a very robust hypoxia-related marker. 
Monocarboxylate transporters 1 and 4
Monocarboxylate transporters (MCT’s) have been discovered to play an important role in 
tumour cell metabolism. Due to the high rate of glycolysis in malignant tumours, large 
amounts of lactic acid are produced. MCT’s facilitate the uptake and excretion of 
monocarboxylates, like lactate and pyruvate, and act as monocarboxylate-proton 
symporters.82 MCT4 is a low-affinity / high capacity lactate transporter, which is abundantly 
present in highly glycolytic muscle cells. It is one of the many target genes of hypoxia-
inducible factor 1 (HIF-1), hence upregulation occurs under hypoxic conditions.83 MCT1 is 
a high-affinity, low capacity monocarboxylate transporter, found in normal tissues like the 
intestinal epithelium (executing an important role in organic acid absorption), the blood 
brain barrier, red blood cells and skeletal muscle cells. Its expression seems to be regulated 
by multiple signaling pathways, microenvironmental parameters, changes in substrate 
concentration and pH.82 They are suggested to play an important role in the symbiosis 
between lactate-producing and lactate consuming tumour cells.33
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with head and neck cancer were randomised, the locoregional control rate was 
significantly higher (49% versus 33%) when radiotherapy was combined with nimorazole 
compared to radiotherapy alone.93 Nimorazole has not been adopted widespread as a 
standard treatment despite these promising results. The many negative studies with the 
older nitroimidazoles have contributed to this circumstance and a second randomized 
trial has never been performed. 
To conclude, over the past years several hypoxia-based treatment strategies have been 
successfully applied in head and neck cancer patients. A meta-analysis shows improved 
locoregional control, disease-specific survival and overall survival with the addition of 
hypoxic modification to radiotherapy, emphasizing the importance of a hypoxia-modify-
ing treatment regimen in head and neck cancer.94 
Outline of the thesis
The aim of this thesis is to investigate the possibility to select patients with a laryngeal 
carcinoma for hypoxia-modifying treatment with ARCON based on immunohistochemi-
cal features. The relationship of the endogenous markers with hypoxia, as measured by 
pimonidazole, is investigated. Elucidating more about the response to hypoxia and 
establishing the value of the different markers may lead to the development of a predictive 
profile that enables the selection of patients for hypoxia-modifying treatments.
In Chapter 2 the results of a large randomised trial in patients with laryngeal cancer 
comparing ARCON with accelerated radiotherapy alone are reported. The excellent local 
and regional control rates with ARCON in patients with a carcinoma of the larynx in a 
phase II study prompted this multicenter phase III study. A translational side study with the 
exogenous hypoxic marker pimonidazole adresses the issue of selecting patients based 
on the oxygenation status of the primary tumour.
As pimonidazole has the disadvantage of pre-biopsy administration, the quest for 
endogenous markers begins in Chapter 3, where a method is described to assess the 
colocalization of multiple markers in different subcellular compartments. Ki-67, a 
proliferation marker located in the nucleus, and CAIX, a membraneous hypoxia-related 
marker, are immunohistochemically stained to describe the parametric mapping method. 
The method is validated against manual scoring and results in multiple biopsies are 
compared.
Chapter 4 focuses on endogenous markers involved in cancer cell metabolism and their 
relation with hypoxia. Cancer cells often have a changed metabolism and depend more 
III trial with CON for bladder cancer shows an increase of the 3-yr local relapse-free survival 
from 43% to 54% and of the overall survival from 46% to 59%.90 The late morbidity was 
similar in both treatment arms. The additional costs (carbogen, nicotinamide) of ARCON 
are very low, making it a cost-effective regimen.
Hypoxic cytotoxins
Bioreductive drugs, like tirapazamine (TPZ), exhibit a direct cytotoxic effect on hypoxic 
cells. In the absence of oxygen, reduction of TPZ takes place, forming a highly reactive 
radical, which induces DNA damage. TPZ has proven its therapeutic value in combination 
with cisplatin in a phase III randomized trial in stage IIIB and IV non-small-cell lung cancer, 
increasing the 1-year survival from 23% to 34%.(von-Pawel et al, 2000) Conversely, the 
combination of TPZ with cisplatin and radiotherapy in advanced head and neck cancer 
showed no improvement in failure-free survival and overall survival.91 Unfortunately, no 
hypoxia-based selection of patients has been made in this trial, while a previous phase II 
study showed the effectiveness of this treatment regimen in patients with detectable 
hypoxia on a [18F]-fluoromisonidazole positron emission tomography scan (FMISO-PET).92
Radiosensitisers
Nitroimidazoles are chemical compounds that mimic the radiosensitising effect of oxygen 
by inducing free-radical mediated double strand DNA breaks. The use of the first 
generation drug misonidazole, the most thoroughly documented of the nitroimidazoles, 
is obsolete in clinical practice as a radiosensitiser, due to its severe side effects. However, it 
still has the attention of some researchers as a PET-imaging compound at substantially 
lower doses. Of the other nitroimidazoles, nimorazole has proven its value as a hypoxic 
cell sensitising agent. In the Danish Head and Neck Cancer 5 study, in which 422 patients 
Fig. 5  The concept of ARCON therapy.
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Introduction
Functional larynx preservation is a main goal when treating patients with loco-regional 
advanced laryngeal cancer.1,2 The combination of radiotherapy with concurrent cisplatin 
demonstrated better larynx preservation and loco-regional control compared to 
conventional fractionated radiotherapy alone.2 However, conventional fractionated 
radiotherapy is currently not considered the optimal strategy for head and neck cancer. 
Based on accomplishments of radiobiological research, new approaches in clinical 
radiotherapy have been developed to improve treatment outcome.
 In head and neck cancer, tumor cell repopulation and tumor hypoxia are known 
factors determining radiation response. Accelerated Radiotherapy plus Carbogen and 
Nicotinamide (ARCON) is a strategy to counteract these resistance mechanisms.3 To limit 
clonogenic repopulation during therapy, the overall duration of radiotherapy is reduced 
by delivering multiple fractions per day. This approach, referred to as accelerated 
fractionation (AR), has demonstrated superior loco-regional control rates in head and 
neck cancer.4,5,6 ARCON combines accelerated radiotherapy with the inhalation of 
carbogen (98% O2 + 2% CO2) to decrease diffusion-limited hypoxia and the administration 
of nicotinamide, a vasoactive agent, to decrease perfusion-limited hypoxia.7,8,9,10,11,12 Phase I 
and II trials have shown the feasibility and tolerability of ARCON for head and neck cancer 
and have produced promising results in terms of tumor control.13,14,15 A favorable 5-year 
local control rate of 80% was obtained in a series of 79 T3 and T4 larynx carcinomas.14 
 This provided the basis for a multicenter trial randomizing patients with cT2-4 
laryngeal cancer between AR and ARCON, of which the results are reported here. Data 
from this study on acute toxicity and compliance have been published recently.16 
 Additionally, in a translational side study the value of a tumor hypoxia assay to predict 
response to ARCON was assessed. For this purpose pimonidazole was used, a bioreductive 
chemical probe that forms protein adducts in viable hypoxic cells and can be visualized in 
tumor biopsies by immunofluorescence.17 
Patients and methods
Study Design and Eligibility
This was an open-label, randomized phase III trial comparing AR with ARCON in laryngeal 
cancer. The trial was conducted under the auspices of the Dutch Head and Neck Cancer 
Group and the Dutch Cancer Society (KWF) in 7 centers in 2 countries (Table 1). 
 Eligibility was assessed by a multidisciplinary head and neck oncology team. 
Diagnostic workup consisted of full history and physical examination, blood cell count 
and blood biochemistry, laryngoscopy under general anesthesia with biopsy taking, CT- 
or MR-imaging of the larynx and neck, ultrasound-guided fine needle aspiration of 
Abstract
Purpose
To report the results from a randomized trial comparing Accelerated Radiotherapy (AR) 
with Accelerated Radiotherapy plus Carbogen and Nicotinamide (ARCON) in laryngeal 
cancer.
Methods
Patients with cT2-4 squamous cell laryngeal cancer were randomized to AR (68 Gy within 
36-38 days) or ARCON (AR plus carbogen inhalation and nicotinamide).To limit the risk of 
laryngeal necrosis, ARCON patients received 64 Gy on the laryngeal cartilage. The primary 
endpoint was local control. Secondary endpoints were regional control, larynx 
preservation, toxicity, disease-free survival and overall survival. In a translational side study 
the hypoxia marker pimonidazole was used to assess the oxygenation status in tumor 
biopsies.  
Results 
From 04-2001 to 02-2008, 345 patients were accrued. After a median follow-up of 44 
months, local tumor control rate at 5 years was 78% for AR versus 79% for ARCON (p=0.80) 
with corresponding larynx preservation rates of 84% and 87% (p=0.48). The 5-year regional 
control was significantly better with ARCON (93%) compared to AR (86%, p=0.04). The 
improvement in regional control was specifically observed in patients with hypoxic 
tumors and not in patients with well-oxygenated tumors (100% versus 55% respectively, 
p=0.01). AR and ARCON produced equal levels of toxicity.
Conclusions 
Despite lack of benefit in local tumor control for advanced laryngeal cancers, a significant 
gain in regional control rate, with equal levels of toxicity, was observed in favor of ARCON. 
The poor regional control of patients with hypoxic tumors is specifically countered by 
ARCON treatment.
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suspect lymph nodes and chest X-ray. All patients over the age of 18, WHO performance 
status ≤1 and squamous cell carcinoma of the larynx and the following clinical stage 
(TNM-classification, UICC 1997), were considered for this study: T2 glottic carcinoma with 
impaired cord mobility or subglottic extension, T2 supraglottic carcinoma with invasion of 
the mucosa of the base of tongue or vallecula or invasion of the medial wall of the piriform 
sinus, T3-4 glottic or supraglottic carcinoma and any N-stage but M0. 
 Exclusion criteria included prior or concurrent treatment for this tumor, severe stridor 
with impossibility for adequate debulking of airway, impaired renal and/or hepatic 
function (creatinine > upper normal limit, ASAT/ ALAT >1.5 times upper limit), use of 
nefrotoxic or anti-convulsant medication that could not be discontinued and a history of 
malignancy during the previous 5 years (with exception of basal cell carcinoma of the skin, 
carcinoma in situ of the cervix or superficial bladder cancer).
 Approval for the study was obtained from the Radboud University Nijmegen Medical 
Centre research Ethics Committee with ratification from each centre before start. Written 
informed consent and completed quality of life questionnaire were obtained before 
randomization.
Sample Size
The target sample size was 344 patients (n= 172 per arm), determined to provide 80% 
power to detect a difference of 60 vs. 75% in local control rate at 2 years for AR vs. ARCON, 
respectively, allowing for dropouts and a significance level of 0.05 (two-sided log-rank 
test). Follow-up of 2 years after the last inclusion, was respected before data analysis. 
Randomization and masking
Patients fulfilling enrollment criteria were centrally randomized by phone at the IKO 
(Integraal Kankercentrum Oost) trials office. Treatment arm assignments (AR vs. ARCON) 
were stratified for tumor site (glottic vs. supraglottic) and institution. A dynamic allocation 
method was used to avoid imbalance of treatment assignment within an institution. 
Randomization took place after all study investigations and no longer than 4 weeks prior 
to the anticipated start of treatment. Data were unmasked.
Treatment
A CT-scan in treatment position with immobilization device was used in all the patients. 
The initial radiation planning target volume encompassed the primary tumor and the 
lymph node levels II, III and IV in case of cN0. Level V and VI were included in case of cN1-3 
and >1.0 cm subglottic extension, respectively.18 The boost planning target volume 
encompassed the primary tumor volume and the macroscopic involved lymph nodes. A 
total dose of 44 Gy in 22 daily fractions of 2 Gy was prescribed followed by a boost dose 
of 24 Gy in twice daily fractions of 2 Gy with a minimum interval of 6 hours between the 
fractions. Dose specification and dose homogeneity requirements were according to 
Table 1  Patient Demographics and Clinical Characteristics
Demographic or Clinical Characteristic AR 
(n = 174)
ARCON 
(n = 171)
No. of 
Patients
% No. of 
Patients
%
Age, years
Median          60 61
Range      38–88 41–84
Sex
 Male          136 78 142 83
 Female          38 22 29 17
Performance status
 0          140 80 137 81
 1          34 20 34 19
Site of the primary tumor
 Supraglottic          100 57 97 56
 Glottic          74 43 74 44
T stage
 T2          67 38 55 32
 T3          80 46 95 56
 T4          27 16 21 12
N stage
 N0          117 67 116 68
 N1          20 12 23 13
 N2a          4 2 7 4
 N2b          10 6 5 3
 N2c          23 13 20 12
 N3          0 0 0 0
Participating institutions*
Radboud University Nijmegen Medical Centre, Nijmegen 75 43 76 44
University Medical Center Utrecht, Utrecht 38 22 39 23
VU University Medical Center, Amsterdam 21 12 20 12
University Medical Center Groningen, Groningen 15 9 13 8
Maastricht University Medical Centre, Maastricht 15 9 13 8
Leiden University Medical Center, Leiden 8 4 9 5
Mount Vernon Hospital, Northwood, United Kingdom 2 1 1 0
Abbreviations: AR, accelerated radiotherapy; ARCON, accelerated radiotherapy plus carbogen and nicotinamide; 
VU, Vrije Universiteit.
* All institutions, except Mount Vernon Hospital, are in the Netherlands.
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metastasis, or death from any cause. Overall survival was defined as time to death. For 
larynx preservation, treatment was considered to have failed on the date laryngectomy 
was performed. 
 Statistical analyses were performed using SPSS 16.0.1. Survival estimates were 
obtained using the Kaplan-Meier method and all analyses were based on intent-to-treat 
policy. All intervals were calculated from the date of randomization and censored after 60 
months or at last follow-up. Differences were compared using the log-rank test and hazard 
ratios (HR) and their 95% confidence interval (CI) were obtained using the Cox proportional 
hazards model. Differences in prevalence of worst grade acute and late toxicities between 
both treatment arms were compared using the Chi-square test. 
Results
Patient Characteristics and Protocol Compliance
Between April 2001 and February 2008, 345 patients were randomized to either AR or 
ARCON (Figure 1). The median follow-up time was 44 (range 18-103), 55 and 60 months for 
the whole group and for patients still alive receiving AR and ARCON, respectively. Patient 
demographics and clinical tumor characteristics were well balanced without significant 
differences between the groups (Table 1). Compliance to radiotherapy, carbogen breathing and 
nicotinamide intake was high.16 Radiotherapy was delivered as planned to 173 (99%) AR 
and 169 (99%) ARCON patients and was completed within the specified time of 38 days 
for 168 (97%) AR and 163 (96%) ARCON patients. Full compliance to carbogen breathing, 
nicotinamide intake and the combined treatment (ARCON) was 86%, 80% and 76%, 
respectively. 
Tumor Control and Survival
Five-year larynx preservation rates were 84% and 87% for AR and for ARCON (p = 0.48). 
There was no significant difference in local control rate: 80% and 78% for AR versus 83% 
and 79% for ARCON at 2 and 5 years, respectively (HR 0.94; CI 0.58–1.52; p=0.80; Figure 2A). 
The 2- and 5-year regional control rates were significantly better with ARCON (88% and 
86% for AR versus 95% and 93% for ARCON, respectively (HR 0.46; CI 0.22-0.97; p=0.04; 
Figure 2B). No significant differences were found for DFS (HR 0.75, CI 0.50–1.13, p=0.16; 
Figure 2C) and OS (HR 1.03; CI 0.73–1.46; p=0.86; Figure 2D). In exploratory subgroup 
analysis we did not find significant differences in 5-year local control rate between 
treatment arms when stratified for T-stage or laryngeal subsite.  
 Salvage laryngectomy was attempted in 29 of 35 AR and 21 of 28 ARCON recurrences. 
Salvage neck dissection was attempted in 12 of 21 and 8 of 12 patients treated by AR and 
ARCON, respectively. The ultimate 5-year local and regional control rates, including salvage 
therapy were 94% vs. 92% (p=0.60) and 92% vs. 98% (p=0.21) for AR and ARCON, respectively. 
Fig 1. CONSORT flowchart. AR, Accelerated Radiotherapy; ARCON, Accelerated Radiotherapy plus Carbogen and 
Nicotinamide. 
Fig 2. Kaplan-Meier curves for local control (A), regional control (B), disease-free survival (C) and overall survival (D) 
comparing accelerated radiotherapy only (AR) or accelerated radiotherapy plus carbogen and nicotinamide (ARCON). 
Log-rank P values are shown and number of patients at risk against yearly intervals.
Report 50 of the ICRU.19 The overall treatment time was 36-38 days. Because a decrease in 
radiation tolerance was observed for cartilage and spinal cord in earlier studies with 
hypoxic sensitization, the total dose to the arytenoid cartilage and the spinal cord in the 
ARCON arm was limited to 64 and 40 Gy, respectively.20,21
 Patients allocated to the ARCON arm received carbogen (98% O2 + 2% CO2, 4 minutes 
before and during daily fractions) and oral nicotinamide (60 mg/kg, 1-1.5h before each 
fraction) concurrently with radiotherapy.22,23 During the boost nicotinamide was given 
only before the first fraction of the day. To prevent nausea, domperidone (10 mg, thrice- 
daily dosage) was given. 
Hypoxia marker side study
After informed consent, patients received pimonidazole (Hypoxyprobe-1; Natural Pharmacia 
International, Belmont, MA) intravenously (500 mg/m2) two hours before biopsy taking. 
Biopsies were snap frozen in liquid nitrogen, immunohistochemically stained and semi- 
automatically analyzed as described earlier.24 Of each biopsy, one complete section was 
analyzed to define the hypoxic fraction, i.e. the area positive for pimonidazole relative to 
the total tumor area. Based on previous pimonidazole marker studies, a cut-off value of 
2.6% was used to dichotomize between well-oxygenized and hypoxic tumors.
Monitoring During Treatment and Follow-up Evaluations
Acute radiation toxicities were graded according to an earlier validated list of toxicity 
criteria (online only table 1).13 Any other side effects felt to be related to carbogen or 
nicotinamide and the reason for interruption or discontinuation were recorded as well. 
After resolution of the acute radiation toxicities, follow-up visits took place every 2, 3, 4 
months during the first, second and third year respectively, then every 6 months for 
another 2 years. The larynx was assessed by fiberoptic or indirect laryngoscopy. Regional 
control was assessed by palpation of the neck. On suspicion of nodal recurrence an 
ultrasound with fine needle aspiration cytology was performed. Recurrences were 
cytologically or pathologically confirmed and documented by CT-scan or MRI. Eligibility 
for salvage neck dissection was assessed by a multidisciplinary head and neck oncology 
team. Severe adverse events were defined as either events that are fatal, life-threatening 
or resulting in permanent disability or any late toxicity like deep mucosal necrosis, cartilage 
necrosis or osteoradionecrosis requiring surgery.
Endpoints and Statistics
The primary endpoint of the study was local tumor control. Local control was taken as 
freedom of first recurrence at the primary tumor site. Secondary endpoints were regional 
control, larynx preservation, toxicity, quality of life, disease-free survival (DFS) and overall 
survival (OS). Regional control was defined as freedom of first regional recurrence. 
Disease-free survival was defined as the time to a local or regional recurrence, distant 
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acute mucositis (severe pain on swallowing: 53% vs. 58%, p=0.37; nasogastric tube feeding: 
28% vs. 28%, p=0.98, narcotic medicines required: 58% vs. 58%, p=0.97). There was a small 
but statistically significant difference in median duration of confluent mucositis in favor of 
AR (2.0 vs. 3.0 weeks, p=0.01). 
 Analysis of late radiation morbidity did not reveal significant differences between AR 
and ARCON for skin and subcutaneous tissues (severe teleangiectasia: 8% vs. 8%, p=0.56; 
severe subcutaneous fibrosis: 7% vs. 9%, p=0.26; severe subcutaneous edema, 8% vs. 4%, 
p=0.09) and mucous membranes (mucosal ulceration, 8% vs. 6%, p=0.36; nasogastric 
tube feeding, 6% vs. 6%, p=0.61), respectively. Twelve patients in the AR group and 6 
patients in the ARCON group received a tracheostomy for severe edema with dyspnea 
Translational side study
Two centers participated in the hypoxia marker study and included 79 patients. The 
hypoxic fraction, as defined by pimonidazole staining, varied from 0-19.4% with a median 
value of 1.5%. There was no ascertainable benefit from ARCON with regard to local control, 
neither in the well-oxgenated tumors, nor in the hypoxic tumors (Figure 3A,B). However, 
regional control in the group with a high hypoxic fraction was significantly improved with 
ARCON compared to AR (100% vs. 55%, p=0.01), while no difference between the 
treatment arms was observed in the group with a low hypoxic fraction (96% for ARCON vs. 
92% for AR, p=0.70) (Figure 3C,D). Patients with hypoxic tumors had a substantially higher 
five-year DFS in the ARCON arm (86%) compared to AR (40%), although the difference did 
not reach the significance level (p=0.08) (Figure 3E,F). No DFS benefit from ARCON was 
observed in patients with well oxygenated tumors (80% for ARCON vs. 77% for AR, p=0.80). 
Toxicity 
Toxicity data have been described extensively in a recent publication.16 Between both 
treatment arms (AR vs. ARCON) no statistically significant difference was observed for 
incidence of acute skin reactions (moist desquamation: 56% vs. 58%, p=0.80), acute 
mucosal reactions (confluent mucositis: 79% vs. 85%, p=0.14) and symptoms related to 
Fig. 1  CONSORT flowchart. AR, Accelerated Radiotherapy; ARCON, Accelerated Radiotherapy plus 
Carbogen and Nicotinamide.
Fig. 2  Kaplan-Meier curves for local control (A), regional control (B), disease-free survival (C) and 
overall survival (D) comparing accelerated radiotherapy only (AR) or accelerated radiotherapy plus 
carbogen and nicotinamide (ARCON). Log-rank P values are shown and number of patients at risk 
against yearly intervals.
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and/or stridor. All patients who developed a cartilage necrosis could be managed 
conservatively. Four of them did receive a tracheostomy (n=1 for AR, n=3 for ARCON) and 
there was no need for laryngectomy. One year after diagnosis 9% of the patients with the 
larynx in situ assigned to AR and 7% of patients in the ARCON group could swallow only 
soft foods or liquids and 3% of patients in both groups needed nasogastric tube feeding 
(p=0.88). 
Severe adverse events
One patient (AR) died from a cardiac arrest during treatment. The cause of death was 
unrelated to treatment. Another patient (ARCON) died one day after the end of treatment 
due to a gastric bleeding. He was using diclofenac for abdominal pain. Causality with 
nicotinamide was considered uncertain for this patient. Upper airway obstruction during 
radiotherapy, requiring tracheostomy, occurred in 4 patients treated by AR and in 1 patient 
with ARCON. Furthermore, in the ARCON arm one patient developed a renal insufficiency 
and sepsis and one patient was admitted to the hospital with severe bleeding from the 
tumor. 
Discussion
The addition of carbogen and nicotinamide to a schedule of accelerated radiotherapy 
produces a significant gain in regional control relative to accelerated radiotherapy alone 
but no benefit in local control in patients with T2-T4 laryngeal cancer. This improvement 
in regional control can be entirely attributed to the patients with hypoxic tumors as 
assessed by pimonidazole staining.
 Although there was no improvement in local control with ARCON, the result in the 
experimental arm was consistent with the 80% local control rate at 5 years obtained in the 
preceding phase II ARCON trial.14 Unexpectedly, the local control rate in the control arm 
was higher than the 63-76% and 43-50% local control rates observed for T3 and T4 
laryngeal cancers treated by hyperfractionated and accelerated regimens reported at the 
time of onset of this study.25,26 A possible explanation might be stage migration due to 
better diagnostic imaging, especially when comparing the results of a prospective study 
with retrospective reports of 15 years ago. In the current study no significant differences 
between T-stages were observed. With conventional fractionation schedules local control 
rates are in the order of 67-80%, 30-77% and 26-52% for T2, T3 and T4 tumors, respectively, 
indicating that patients with more advanced local disease profit most from accelerated 
fractionation.27,28,29,30,31 
 Because the purpose of this study was to arrive at improved tumor control with no 
increase of late laryngeal toxicity, a dose reduction to 64 Gy for the larynx was prescribed 
for patients in the ARCON arm. This dose reduction was based on a decrease in radiation 
Fig. 3  Local control (A,B), regional control (C,D) and disease-free survival (E,F) by oxygenation 
status of the primary tumor and treatment arm. Log-rank P values are shown and number of patients 
at risk against yearly intervals.
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improvement in local relapse rate, bladder conservation rate and overall survival. The 
additional costs (carbogen, nicotinamide) of ARCON are very low, making it a cost-effective 
regimen.
 The present study demonstrates the importance of a proper patient selection that is 
based on the mode of action of the treatment under investigation, as only patients with 
hypoxic tumors did profit from ARCON therapy and no gain was seen in patients with 
well-oxygenated tumors. This finding strongly supports the notion that assessment of the 
tumor oxygenation status provides a powerful selection tool for hypoxia-modifying 
treatment on an individual patient basis. The inclusion of unselected patient populations 
may be an important reason for the modest improvements generally reported by studies 
employing hypoxic modification.33,37 Further translational research linked to this study is 
currently investigating the predictive value of a hypoxia-associated gene signature.
Conclusion
The use of ARCON in stage II-IV laryngeal cancer produced a significant gain in regional 
control rate compared to AR, with similar acute and late toxicity. There was no difference 
in local control between the treatment arms. Translational research employing a hypoxia 
marker assay demonstrates that proper patient selection based on tumor biology is the 
key to the success of this approach. 
tolerance in the order of 10% observed for cartilage when radiotherapy was given in 
hyperbaric oxygen.20 In the current study a similar effect was expected from normobaric 
carbogen with nicotinamide. This 4 Gy absolute dose difference on the larynx is a possible 
explanation for the lack of additional benefit in local tumor control with ARCON as 
compared to AR alone. Based on clinical data, dose-response curves have been 
constructed for head and neck carcinomas.32 From these, dose-response gradients 
(gamma value) have been derived as a measure of the steepness of the curve. Typical 
gamma values for larynx carcinoma range from 1.5-2.5. This means that for each percent 
increment in dose, the probability of controlling the tumor will increase by approximately 
2 percentage points. Given the same local control but with 4 Gy less dose, an enhancement 
of tumor control probability of 10-15% can be derived when carbogen and nicotinamide 
are combined with radiotherapy. Thus, although a dose difference of 4 Gy seems modest, 
the corresponding difference in cure rate is significant. 
 In contrast to the primary tumor, the dose delivered to the lymph node metastases in 
the current study was similar (68 Gy) in both arms. The addition of carbogen and 
nicotinamide did lead to a significant improvement of 8% in regional control rate. This 
finding is consistent with the results of a recent systematic review and meta-analysis of 
hypoxia modification in head and neck cancer in which an absolute risk reduction of 8% 
for loco-regional control was observed.33 
 The high rate of local and regional control rates in both treatment arms of the current 
trial and the potential to perform successful salvage surgery in case of recurrence explains 
the lack of benefit in overall survival, similar to what is observed after conventional 
radiotherapy with concurrent cisplatinum in the RTOG 91-11 study.2 
 In the current study, long-term swallowing function was similar for AR and ARCON. 
One year after treatment, swallowing was limited to soft foods or liquid in 9% and 7% of 
patients respectively. This is lower than the 23% reported in RTOG 91-11.2 However, direct 
comparison is difficult because of potential bias, e.g. RTOG 91-11 included more 
supraglottic tumors. Furthermore, unlike the current study, planned neck dissection was 
performed in case of cN2a or cN2b disease. Neck dissection after chemoradiotherapy has 
been demonstrated to increase the risk of long-term dysphagia and laryngeal 
dysfunction.34 
 Recently published data from this study demonstrate that ARCON results in a high 
level of compliance and a toxicity profile, comparable to what is encountered after 
accelerated radiotherapy alone.16,35 The 8% improvement in regional control and excellent 
larynx preservation rate support the evidence that ARCON can achieve a therapeutic gain. 
Probably, head and neck tumors at other subsites, where the laryngeal cartilage is not the 
dose-limiting organ, e.g. oropharynx, will profit more from ARCON, especially those with 
advanced nodal stage. The recently published results from a phase III trial with carbogen 
and nicotinamide for bladder cancer confirm the value of this hypoxia-modifying 
approach.36 Radiotherapy with carbogen and nicotinamide produced a significant 
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Introduction
In cancer research immunohistochemistry is an important technique to characterize 
protein expression in tumors, while preserving tissue morphology. By clarifying aberrant 
overexpression of proteins, prognostic factors can be discovered and highly specific 
therapies can be developed. A well-known example of such a tumor-specific marker is 
Her-2/neu in breast cancer.1
 Immunohistochemistry is based on an antibody-antigen interaction, combined with 
various detection techniques.2 A frequently used method is based on a peroxidase-
catalyzed reaction. The enzyme is conjugated to the primary (direct method) or secondary 
(indirect method) antibody and by adding diaminobenzidene (DAB) the labelled antibody 
is visualized by brown staining. The staining can be accentuated by counterstaining with 
haematoxylin, which stains the background tissue blue.
 The interpretation of immunostains has made a rapid development from manual 
counting to fully automated techniques for image capture and analysis.3,4,5 Although 
visual evaluation cannot be replaced entirely by these methods, automated image analysis 
has some major advantages. In clinical practice for instance, it increases throughput and 
reproducibility.6 Furthermore, in recent research even localization of protein expression at 
the subcellular level was achieved7, illustrating the additional possibilities of automated 
analysis over manual counting. Finally, manual interpretation is subject to high 
interobserver variability and is semi-quantitative at best5, whereas in a research setting 
quantitative information on a continuous scale can be of great importance. 
Several systems for analysis have been described, varying in software, threshold selection, 
colour format and algorithms.8 The reports on quantitative automated image analysis 
focus on various parameters, like vascular density9, nuclear staining or intensity of 
staining4,10. Automatic quantification of the fraction of a membrane-bound protein poses 
some difficulties, although automated filling operations are applied to facilitate this 
analysis11,12. Intensity-based quantification of a membrane-bound protein has been 
described using a membrane isolation algorithm.13
 The automated evaluation of multiple markers is a challenging issue. Most of the 
automated analysis methods that are available concentrate on one marker at a time. 
Whereas, especially in tumor cells, the co-localization of different markers can provide 
valuable information. The exact co-localization on a cellular level is difficult to assess when 
the markers have a different intracellular location, e.g. nuclear and membranous. Here, the 
absence of overlap on pixel level renders a binary image map comparison14 unsuitable. 
Parametric mapping can solve this problem by creating an analysis grid defining square 
regions of multiple pixels. With this technique the whole image is subdivided in small 
squares. The information of all immunopositive objects or pixels within a square can be 
translated into numerical data, e.g. cell number, mean staining intensity, number of 
positively stained pixels etc. Different parameters can be combined in one value, like 
Abstract
Purpose 
Automated analysis of immunohistochemically stained tissue sections is of great 
importance in cancer research to detect tumor-specific prognostic markers and make 
therapy decisions. Here, an automated quantitative analysis is presented to assess the 
colocalization of CAIX, a membrane-bound hypoxic marker and Ki-67, a nuclear 
proliferation marker. 
Methods 
Tissue sections of 104 biopsies from 89 patients were stained for CAIX and Ki-67 with 
diaminobenzidine and haematoxylin counterstain. Image scans of whole tumor sections 
were recorded and image maps were created with parametric mapping to quantify the 
markers and assess the colocalization. 
Results 
The fraction of CAIX showed a range of 0 – 93%. The interobserver correlation and the 
correlation between manual scores and automated analysis were both very strong 
(rs = 0.96, p < 0.0001, and rs = 0.97, p < 0.0001). The labelling index of Ki-67 exhibited a range 
of 0 –42% with less strong interobserver and manual to automated analysis correlations 
(rs = 0.90, p < 0.0001, and rs = 0.71, p < 0.0008). The relative tumor area positive for both 
markers varied from 0 – 76%. 
Conclusion 
Parametric mapping of immunohistochemically stained tumor sections is a reliable 
method to quantitatively analyze membrane-bound proteins and assess the colocalization 
of various tumor markers in different subcellular compartments.
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Immunohistochemistry
Sections were deparaffinised in Histosafe (clearing agent, Adamas, the Netherlands), 
rehydrated through a graded ethanol series and boiled for 30 minutes in antigen retrieval 
solution. After cooling for 25 minutes and rinsing in PBS, endogenous peroxidase was 
blocked with 3% H2O2 in methanol. Then, sections were incubated with 5% normal 
donkey serum in PAD (primary antibody diluent, Abcam, UK) to block aspecific binding.
 Sections were incubated at 4 °C overnight with mouse-anti-CAIX (E. Oosterwijk, 
department of Urology, Radboud University Nijmegen Medical Centre) diluted 1:25 in PAD 
or rabbit-anti-human Ki-67 (Abcam, UK) diluted 1:50 in PAD. Subsequently, the biotinylated 
secondary antibodies were applied; biotin-labelled-F(ab’)2-donkey-anti-mouse IgG 
(Jackson Immuno Research) for CAIX and biotin-labelled-F(ab’)2-donkey-anti-rabbit IgG 
(Jackson Immuno Research) for Ki-67, followed by ABC-reagent (Vector Elite kit, Vector 
Laboratories) for 30 minutes. Peroxidase activity was detected with diaminobenzidine 
(DAB). Finally, sections were counterstained with haematoxylin for 30 seconds and 
mounted with KP mounting medium (Klinipath, Duiven, the Netherlands). For negative 
controls, PAD was added without the primary antibody.
Image processing
A digital image processing system for fluorescence microscopy21 was adapted to scan 
immunohistochemically stained sections using bright field microscopy. This system consisted 
of a monochrome CCD camera (Retiga SRV, 1392 x 1040 pixels) and a RGB filter (Slider Module; 
QImaging, Burnaby, BC, Canada) attached to a motorized bright field microscope (DM6000 
Leica, Wetzlar, Germany). Whole tumor sections were scanned with a 10 x objective at 100x 
magnification using a Macintosh computer running IPLab for Macintosh (Scanalytics Inc., 
Fairfax, VA, USA), which controlled this motorized system and generated 24-bit colour 
composite images (pixel size 1,8 µm). For every scan session a separate background image 
was recorded from an individual microscopic field in one focus plane and used to construct 
composite background images corresponding in size with the tumor section scans.
 To extract and separate the individual colours from the DAB (brown) and haematoxylin 
(blue) signals, the RGB linear unmixing module in the TRI2-software (P.R. Barber, R. Locke, 
R. Edens, S. Ameer-Beg, B. Vojnovic and J. Gilbey; Randall Division and Gray Institute) was 
applied using the “Absorption” mode with a nonnegative least squares algorithm22. This 
resulted in grayscale images in which the pixel values represent the concentration of a 
marker (Figure 1, second panel, pseudo-coloured). 
 The colours to which the images were unmixed were obtained from previously saved 
reference files. In these files colour information was stored from the blue (haematoxylin) 
and brown (Ki67, CAIX) signals and was selected in images that were acquired from 
single-stained control sections. During linear unmixing, the RGB colour image was 
corrected for the microscope illumination by using the ‘background’ image. For further 
processing of the grayscale images, cut off values for the DAB and haematoxylin signals 
presence or absence of colocalization, and can be assessed for the whole tissue section. 
Thus, colocalization can be determined on a near-cellular level instead of a pixel level. This 
technique has been described previously in a different field of research for the assessment 
of the immunopositive cell density in the rat brain.15 An advantage of this method is the 
retainment of intensity values, reflecting the concentration of the stain in the tissue, which 
would be lost when performing binary analysis.
 In this study we applied the parametric mapping method to examine two important 
features of malignant tumors: proliferation and hypoxia. Proliferation is an important 
prognostic factor in many types of cancer. Highly proliferating tumors are associated with 
more aggressive biological behaviour and a worse prognosis.16,17 Hypoxia is another 
adverse prognostic factor, making tumor cells more resistant to therapy as well.18 A 
combination of these two features could identify a subpopulation of tumor cells that is 
highly relevant for treatment responsiveness.11 Several hypoxia-related markers are 
available to measure the amount of hypoxia in tumors.19,20 For the research presented here, 
carbonic anhydrase IX (CAIX) was used, a membrane-bound endogenous hypoxia-related 
marker to assess the feasibility of this method. In future research other biologically 
connected markers can be investigated, for example epidermal growth factor receptor 
(EGFR) and Ki-67.
 In this study a quantitative computer-assisted analysis of immunohistochemically 
stained sections using parametric mapping is described and evaluated for CAIX, the 
membrane-bound protein, and for the colocalization of CAIX with Ki-67, a nuclear 
proliferation marker, to identify the proliferating hypoxic subpopulation of tumor cells. 
The effect of varying the resolution of the analysis will be presented and the method will 
be correlated to manual scoring. Finally, multiple biopsies from the same tumor will be 
scored to get an indication of the intratumor variability.
Materials and Methods
Samples
Biopsy material obtained for routine purposes of 103 patients diagnosed between 2001 
and 2008 with advanced laryngeal carcinomas was retrieved from the pathology 
department of the Radboud University Nijmegen Medical Centre in the Netherlands. 
From some patients multiple biopsies of the same tumor were available. The biopsies 
were obtained for diagnostic purposes and had been fixed in formaldehyde and paraffin-
embedded. The samples were cut in sections of 5µm. One section was stained for 
haematoxylin and eosin and two consecutive sections for Ki-67 and CAIX, both with a 
haematoxylin counterstain.
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were selected visually above the background staining for Ki-67. For CAIX, one threshold 
could be set for each staining series, based on the mean background of each section 
within the series. The cut off value was defined as the mean background + two times the 
standard variation. To be able to quantitatively compare the overlap of the Ki-67 signal 
and the CAIX stained areas in the consecutive images, CAIX images were rotated and 
shifted to fit as close as possible the Ki-67 images using the interactive “register” function 
in IPLab. A pseudo-coloured image composed of the corresponding grayscale images 
was used to check the match (Figure 1B). Large deviations (> 2 cells disparity) were 
corrected by refitting. In case of a fragmented or damaged tissue section, it was required 
to divide the image in two parts and match and analyse these parts separately.
 Haematoxylin/eosin stained sections were used as a guide to manually delineate the 
tumor area on the Ki-67 image scan in IPLab, excluding normal tissue, necrotic areas and 
artefacts, creating a mask for image analysis.
 
Parametric mapping
As the markers investigated in this study are localized in different subcellular compartments, 
i.e. nucleus and membrane, a newly developed parametric mapping technique was 
applied to reduce the spatial information in the images. Hereto, all grayscale images were 
subdivided in small squares of 20 x 20 pixels, corresponding to a size of 36 µm x 36 µm 
(Figure 1A, third row). This size was chosen based on cell size and small deviations in the 
fitting of consecutive tissue sections. From the Ki-67 image and the corresponding 
haematoxylin image the labelling index of Ki-67 was calculated for every square, defined 
as DAB-positive area divided by the total haematoxylin-stained nuclear area (values 
between 0 and 100). This result was set as a new value in the corresponding square of a 
new image, creating a so-called parameter image map (Figure 1A, fourth row). In the 
corresponding CAIX image, the average intensity of the CAIX staining was measured for 
each square (values between 0 and 255) and set as a new value in the corresponding 
square of a second parameter image map. In all cases, only the pixels with a value above 
the preset cut off value were included. Objects (contiguous groups of pixels above the cut 
off value) smaller than 6 pixels were considered non-specific staining or cutting artefacts 
and were excluded from the analysis. Using these parameter image maps, the CAIX 
positive area and the Ki-67 labelling index for the whole section were calculated. The CAIX 
positive area (or CAIX fraction) was defined as the percentage of squares in the parameter 
image map with values higher than zero. For Ki-67, the labelling index of the whole section 
was calculated by averaging the values of all squares in the parameter image map. 
 The relationship between proliferation and CA-IX expression was analysed by 
determining the overlap for each biopsy. By combining the CAIX image map and the Ki-67 
image map, every square has a value for CAIX and one for Ki-67. Overlap for the whole 
tissue section was defined by the percentage of squares having a value > 0 for both 
parameters, leaving the intensity values out of consideration in the first calculations.
Fig. 1  (A) Overview of the process of image preparation and analysis. Example of an original DAB 
and hematoxylin stained tumor section for Ki-67 and CAIX (top) with the resulting pseudo-colored 
grayscale images after linear unmixing (second row). The third and fourth row show the conversion 
of immunopositive objects into numerical data by parametric mapping using square compartments 
of 20 x 20 pixels. Note the intensity values in the resulting CAIX image map and the labeling indexes 
in the Ki-67 image map. (B) A pseudo-colored image was constructed by merging the Ki-67 (red) 
and CAIX (green) images to check the match with a magnification of the area indicated by the white 
square. Scalebars: 100 mm.
CAIX Ki-67A B
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 After immunohistochemical processing, Ki-67 and CAIX gave a clear brown staining 
with intensities varying gradually from light brown to dark brown. Clear membranous 
CAIX staining was observed in most tissue sections. The frequency distribution of the 
CAIX fraction and the Ki-67 labelling index for all tumors as obtained by automated 
analysis is shown in Figure 2. The CAIX positive area showed a range of 0-93% with a 
median value of 27%. The Ki-67 labelling index varied from 0-42% (median 14%).
 To validate the automated analysis, the results were compared with visual scoring for 
both parameters. The area positive for CAIX showed a strong interobserver correlation 
(rs = 0.96, p = < 0.0001, Figure 3a). Likewise, the correlation between the observers and the 
 To further evaluate this colocalization and explore the possibilities of this method, 
four classes were defined. Class 1 includes squares with CAIX intensity < 100 and Ki-67 
labelling index < 25, representing colocalization of weak staining patterns for both 
markers. Class 4 represents strong colocalization with square values of CAIX ≥ 100 and 
Ki-67 labelling index ≥ 25. Class 2 (CAIX < 100, Ki-67 ≥ 25) and class 3 (CAIX ≥ 100, Ki-67 
< 25) include the squares with one parameter high and one low.
 To evaluate the effect of the size of the squares (or grid size) on the results, the analysis 
was repeated with a square size of 10 x 10 pixels (approximately one cell) and 40 x 40 pixels 
(approximately 16 cells) in a subgroup of 18 tumors.
Manual scoring
To compare manual assessment of both markers with quantitative digital analysis, two 
investigators (S.R. and W.P.) scored the area positive for CAIX on the microscope in a 
subgroup of 17 tumors, blinded for the result of the automated analysis.  The whole tumor 
section was scored semiquantitatively per field of view at 100x magnification, the mean of 
all fields of view representing the final score . The labelling index of Ki-67 was scored in 
three fields of view in representative parts of the tumor section with a 400x magnification 
by counting the positive nuclei and the total number of nuclei in that field. Only dark 
brown stained nuclei were considered Ki-67 positive.
 To validate the colocalization, the percentage of “true” colocalization and the percentage 
of mismatch were determined within the squares (Figure 5c). In 3 sections 200 squares 
were scored for CAIX-positivity, Ki-67-positivity and the presence of true colocalization.
Statistics
Statistical analyses were performed on a Macintosh computer using Prism 4.0 (Hearne 
Scientific software, Dublin, Ireland) software package. To assess the correlation between 
manual and computer-assisted scores and the inter-observer variation the Spearman 
correlation coefficient was calculated and Bland-Altman analyses were performed. Linear 
regression analysis was done to correlate the results of the different grid sizes with the 
manual score. P-values < 0.05 were considered significant.
Results
Biopsy material was obtained from 103 patients and from 15 of these patients two or more 
biopsies were available. All sections were evaluated on their suitability for analysis. 
Fourteen biopsies were excluded, because of the absence of invasive carcinoma or the 
poor quality of the sample. In total, 104 biopsies of 89 tumors were available for analysis. 
The tumor area of all sections ranged from 0.1 mm2 to 26.4 mm2 with a median value of 
3.7 mm2. 
Fig. 2  Results of the automated single marker analysis for CAIX and Ki-67. Frequency distribution of 
the relative area positive for CAIX showed a range of 0 – 93% with a median of 27% (A). Examples of 
tumor sections with a CAIX positive fraction of 3% and 81% are depicted. The labeling index of Ki-67 
varied from 0 – 42% with a median value of 14% (B), with a representative tissue section of 3% and 33%.
A B
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automated analysis was strong (rs = 0.97, p < 0.0001 and rs = 0.93 p < 0.0001) and is shown 
for one of the observers (Figure 3b). Bland-Altman analysis confirmed this correlation with 
a bias of only 0.5. For Ki-67 the interobserver correlation was less strong, but also significant 
(rs = 0.90, p = 0.0001, Figure 3c). Again, the correlation with the automated analysis was 
significant for both observers and is shown for one of them. By using Bland-Altman 
analysis a bias towards higher scores by manual assessment was observed (Figure 3d).
 From 15 patients two biopsies from the same tumor were available for analysis. To get 
an indication of the intratumor variation of CAIX and Ki-67, sections from both biopsies 
were analyzed. The CAIX-positive area and the Ki-67 labelling index both showed a strong 
correlation (rs = 0.81, p = < 0.0003 and rs = 0.89, p = < 0.0001, Figure 4a and b).
The effect of the grid (square) size on the results was evaluated, by using different square 
sizes, varying between 10 x 10, 20 x 20 and 40 x 40 pixels. For CAIX, a course grid resulted 
in higher values and a fine grid in lower values, as can be expected. Beforehand, a grid size 
of 20 pixels was chosen as the preferred size for the analysis, based on average cell size 
and small inaccuracies in the matching of the Ki-67 and CAIX sections. On top of that, the 
results obtained with this grid size had the best fit with the absolute values found by the 
visual scoring of the CAIX area (slope 0.99 (20) slope 0.75 (10) and slope 1.15 (40).
 For the labelling index of Ki-67, varying the grid size from 20 to 10 or 40 showed little 
effect on the results (slopes 0.64, 0.59 and 0.62 respectively), suggesting that the outcome 
is independent of the size of the square compartments.
Fig. 3  Correlation of automated analysis with manual scoring. A strong relationship between CAIX 
score of two observers (rs = 0.96, p < 0.0001) (A) and between automated measurement and manual 
score (rs = 0.97, p < 0.0001) (B) was observed, with a small bias of -0.6 as determined with the Bland-
Altman analysis. For Ki-67, the interobserver correlation was less strong (rs = 0.90, p = 0.0001) (C) and 
the correlation with the automated analysis showed a bias of 4.2, with higher manual scores (D). 
Dashed horizontal lines represent the mean difference and the mean difference plus and minus 1.96 
times the SD of the differences.
Fig. 4  Correlation of CAIX positive area and labeling index of Ki-67 in multiple biopsies of the same 
tumor. Both CAIX (A) and Ki-67 (B) showed a strong correlation (rs = 0.81, p < 0.0003 and rs = 0.89, 
p < 0.0001 respectively).
A
B
C
D
A B
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 As a measure for colocalization the percentage of squares with a value greater than 
zero for both the CAIX parameter map and the Ki-67 labelling index map was calculated 
for each biopsy by juxtaposition of the image maps. A wide range of colocalization was 
observed (0-76%), with a median value of 15% (Figure 5). The percentage of true 
colocalization divided by the total colocalization as calculated from the automated 
analysis was 79%, 82% and 84% for the 3 sections scored. The percentage of mismatch 
(defined by expression of both CAIX and Ki-67 within the same square, but not in the 
same cell,  figure 5C) was 5%, 10% and 8% respectively. The remaining squares showed a 
discordant result due to thresholding differences between visual scoring and the preset 
cut off value for the automated analysis.
 Two examples with a comparable percentage of overall colocalization (28% and 38%), 
but an opposing class distribution, taking into account the intensity of CAIX staining and 
the value of the Ki-67 labelling index, are depicted in Figure 6. In tumor 66 the colocalization 
consists mainly of areas with low CAIX intensity and  high Ki-67 labelling index (class 2). 
In tumor 71-II the class distribution is totally different with 70% of the colocalization consisting 
of areas with high CAIX intensity and low Ki-67 labelling index (class 3).
Fig. 5  Colocalization of CAIX expression and proliferation (labeling index of Ki-67) in biopsies of 
89 laryngeal tumors assessed by parametric mapping. The frequency distribution (A) shows a wide 
range of colocalization (0 – 76 %), with an uneven distribution towards lower values. A peudo-
coloured merged image with an overlay grid illustrates our definition of colocalization in this study (B). 
(C) Schematic representation of mismatch (left) and “true” colocalization (right) within a square.
A
B
C
Fig. 6  Example of two tumors with a different degree of colocalization. The squares of a whole 
tissue section were subdivided into four classes: class 1 contains squares with CAIX intensity < 
100 and Ki-67 labelling index < 25, class 2 CAIX < 100 and Ki-67 ≥ 25, class 3 CAIX ≥ 100 and Ki-67 < 25, 
class 4 CAIX ≥ 100 and Ki-67 ≥ 25. The relative frequency distribution of tumor 66 (A) shows more 
class 2 square compartments, tumor 71-II (B) more class 3, representing a  different degree of 
colocalization.
A Tumour 31 Tumour 71B
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 Although the colocalization of CAIX and Ki-67 cannot be assessed exactly on a cellular 
level, this is a very close approximation. For the analysis of the colocalization the size of the 
square compartments of 20 x 20 pixels seemed appropriate. This size includes at least one 
cell and can correct for small errors in the fitting of consecutive sections, without the loss 
of information. As the deviations in fitting were very small and because of the regional 
pattern of CAIX staining23, this is a decent and viable approach to assess the degree of 
colocalization. This is supported by the finding that only 5-10% mismatch is present, when 
observing the colocalization at the level of the square compartments.
 As becomes clear in Figure 1, information about intensity values of CAIX and labelling 
index of Ki-67 remains present in the parameter image maps. This information was used 
to create classes of colocalization, with class 4 representing the strongest colocalization 
with intense CAIX staining and a high Ki-67 labelling index. This is illustrated in Figure 6 
with the relative frequency distribution of these classes of two different tumors. Tumor 66 
and tumor 71-II have similar overall colocalization rates but show a different distribution of 
colocalization over the various classes, possibly representing dissimilar biological 
behaviour. This is just an example of how the information in the image maps can be used. 
For other parameters alternative calculations and comparisons can be done with 
numerous possibilities.
 Segmentation of the Ki-67 signal was sometimes difficult due to the gradual intensity 
scale and was subject to interpersonal interpretation. The large interobserver variation in 
the manual scores of the labelling index of Ki-67 confirmed this. Other authors have 
encountered this problem as well.24,25 This could possibly be improved by using a different 
staining method, such as immunofluorescence, or altered background stain. Another 
issue is the higher overall labelling index for Ki-67 obtained with manual scoring compared 
to the automated analysis. This is probably due to the intensity scale of the DAB staining 
and the difference of manually counting positive nuclei on the microscope with a 400 x 
magnification and setting a threshold on a tissue image scan. In the first situation the 
estimated cut off value will be lower, resulting in a higher value. However, most importantly, 
the relative scoring of the observers and the automated analysis correlated well, indicating 
that with different observers as well as with the automated analysis tumors are ranked 
similarly.
 As compared to a high throughput method such as tissue microarray, our parametric 
mapping technique is a labour-intensive method due to the delineation of the tumor 
areas and the matching of the tissue sections. However, a large disadvantage of tissue 
microarrays is the use of small tissue cores, leaving the heterogeneity within a tissue 
section out of account and increasing the risk of sampling error. Analysis of whole tissue 
sections is a major advantage of the current method. This is supported by the strong 
correlation seen between CAIX fractions in multiple biopsies from the same tumor. As 
described before, there can be large intratumor heterogeneity with respect to CAIX 
fraction12 and Ki-67 labelling index26. The wide range we observed in CAIX staining (0 – 93 
Discussion
Recognizing specific tumor markers that can predict outcome or response to treatment 
can be of great value in therapy decisions in many different types of cancer. Various single 
markers have already shown prognostic value, but as the aggressiveness of a tumor is a 
complex interaction of different pathways, knowledge about colocalization of multiple 
markers could be of great importance. 
 In this report we describe an automated computer-assisted analysis of immuno-
histochemically stained tumor sections using parametric mapping for simultaneous 
quantification of Ki-67, a nuclear proliferation marker, and CAIX, a membrane-bound 
hypoxia-related marker. We assessed the staining percentages of CAIX and Ki-67 
individually and the percentage area showing colocalization of the two markers. To our 
knowledge, this is the first study that uses the parametric mapping technique to compare 
two biologically connected features located at different subcellular compartments. 
 This parametric mapping method has two strengths. The first is its potential to 
determine the relative tumor area positive for a membrane-bound protein in an accurate 
way, correlating strongly with manual assessment. The second is the measurement of 
colocalization of markers with different intracellular locations for a whole tumor section, 
which is almost impossible to assess by visual scoring. Although we focused on CAIX and 
Ki-67, this method is applicable to many other tumor markers, for example epidermal 
growth factor receptor (EGFR) and Ki-67 or hypoxia-inducible factor 1α (HIF-1α) and CAIX, 
and can therefore be of great significance for future research.
 As our parametric mapping technique requires grayscale images as input, we first 
had to separate the individual colours in the sections. In this study, the resulting images 
obtained by the linear unmixing algorithm were of good quality and, despite a high 
background staining, apt for further analysis. CAIX showed a strong membranous staining, 
of which the cut-off value could easily be set against the background.  The correlation of 
the automated results for CAIX and Ki-67 with manual scoring was high. No systemic 
errors were shown by the Bland-Altman analysis, making the parametric mapping 
technique an accurate method for assessing the relative CAIX-positive tumor area in 
whole tissue sections. Although the results with varying grid sizes all showed a strong 
correlation with visual scores, the linear regression slope of the 20 x 20 pixel square was 
closest to 1. Therefore, in absolute values this was the best estimation compared to 
manual scoring.
 This is a somewhat unexpected finding, as theoretically the ideal square size would 
contain one cell. However, due to heterogeneity in cell size and tissue structure this ideal 
size is difficult to determine. Considering the other goal of our research: assessing the 
overlap of the two markers in consecutive tissue sections, the 10 x 10 pixel square would 
likely be too small. In conclusion, the 20 x 20 pixel size is suitable for analysis of the relative 
positive area of a membrane-bound marker.
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%) can be another explanation for this remarkable finding. A good correlation is more 
likely to occur in a wide range of values, than with small intertumor variations. For the 
Ki-67 labelling index a strong correlation between biopsies was shown as well, although 
the data showed a smaller, but still considerable range (0 – 42 %). Therefore, it can be 
concluded that if the range of observed values is sufficiently wide, a random biopsy could 
give a fairly representative indication of the hypoxic or proliferation status of a tumor. A 
marker with little variability would be less informative anyway as it has less potential to 
discriminate between tumors with different biological behaviour.
 In conclusion, research on verification of specific tumor markers runs parallel to the 
development of targeted therapies. This enables a more elaborate prediction of tumor 
response and the selection of patients for a specific therapy. Automated quantification of 
multiple markers in immunohistochemically stained tumor sections can be of great use to 
achieve this goal. By parametric mapping image maps are created for each marker 
containing numerical data representing a particular biological feature (area, intensity, 
labelling index) quantitatively. Once these image maps are prepared for analysis and a 
threshold is set, multiple analyses can be performed, depending on the research question. 
Moreover, when using multiple markers, the relationship between the corresponding 
biological features can be studied quantitatively independent of their subcellular 
localization, even in adjacent tumor sections. This parametric mapping technique can 
have a wide application in cancer research and patient selection.
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Background
Malignant tumors often exhibit an altered metabolism compared to normal tissues. This 
phenomenon can be explained by several underlying mechanisms. First of all, the genetic 
changes related to a high proliferation rate, as observed in many tumors, lead to an 
increased metabolism.1 Another important reason for a changed metabolism is the 
adaptation of tumor cells to the microenvironment. Due to rapid tumor growth, hypoxic 
areas are frequently encountered. Under circumstances of severe hypoxia, cells are forced 
to use anaerobic glycolysis as their primary energy source, the Pasteur effect.2 Normal cells 
convert to oxidative phosphorylation when oxygen levels are restored. In contrast, tumor 
cells can use aerobic glycolysis even in the presence of sufficient amounts of oxygen. This 
is called the Warburg effect, a manifestation of a modification of the tumor cell 
metabolism.3 Due to a high level of aerobic glycolysis, in many tumor cells, glucose 
consumption is substantially higher than in normal cells.4,5
 The consequence of the high rate of glycolysis in malignant cells is the production of 
large amounts of lactic acid. An interesting observation made by Sonveaux et al. is the 
preference of tumor cells for lactic acid over glucose as the primary energy source.6 This 
creates the perfect conditions for a symbiosis between anaerobic glycolytic cells and 
aerobic tumor cells6 or aerobic stromal cells, as described in colorectal carcinomas.7
 Recently, monocarboxylate transporters (MCT’s) have been discovered to play an 
important role in this symbiosis. These transporters facilitate the uptake and excretion 
of monocarboxylates, like lactate and pyruvate, and act as monocarboxylate-proton 
symporters.8 MCT4 is a low-affinity / high capacity lactate transporter, which is abundantly 
present in highly glycolytic muscle cells. It is one of the many target genes of hypoxia-
inducible factor 1 (HIF-1).9 MCT1 is a high-affinity, low capacity monocarboxylate transporter, 
found in normal tissues like the intestinal epithelium (executing an important role in 
organic acid absorption), the blood brain barrier, red blood cells and skeletal muscle cells. Its 
expression seems to be regulated by multiple signaling pathways, microenvironmental 
parameters, changes in substrate concentration and pH.8 Other important proteins related 
to the metabolism of tumor cells are glucose transporter-1 (GLUT-1), the main transporter 
involved in glucose influx, and lactate dehydrogenase-5 (LDH-5), responsible for the 
conversion of pyruvate into lactate. Like MCT4, these proteins are upregulated under 
hypoxic conditions by HIF-1.10 Another main target for HIF-1 is carbonic anhydrase IX 
(CAIX), a hypoxia-related protein involved in pH regulation11, that shows weak correlations 
with the exogenous hypoxia marker pimonidazole.12,13 The advantage of the use of these 
proteins as endogenous immunohistochemical markers is that no prior infusion of markers 
is necessary and therefore archived material can be used to assess the metabolic and, 
possibly, the hypoxic status of the tumor. However, up until now no endogenous marker 
has been identified that correlates strongly with pimonidazole.14 In this study, we describe 
and quantify the expression patterns and colocalization of several important hypoxia-
Abstract
Purpose 
The cellular response of malignant tumors to hypoxia is diverse. Several important 
endogenous metabolic markers are upregulated under hypoxic conditions. We examined 
the staining patterns and co-expression of HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4 
with the exogenous hypoxic cell marker pimonidazole and the association of marker 
expression with clinicopathological characteristics.
Methods 
20 biopsies of advanced head and neck carcinomas were immunohistochemically stained 
and analyzed. All patients were given the hypoxia marker pimonidazole intravenously 2 h 
prior to biopsy taking. The tumor area positive for each marker, the colocalization of the 
different markers and the distribution of the markers in relation to the blood vessels were 
assessed by semiautomatic quantitative analysis.
Results 
MCT1 staining was present in hypoxic (pimonidazole stained) as well as non-hypoxic 
areas in almost equal amounts. MCT1 expression showed a significant overall correlation 
(r = 0.75, p < 0.001) and strong spatial relationship with CAIX. LDH-5 showed the strongest 
correlation with pimonidazole (r = 0.66, p = 0.002). MCT4 and GLUT-1 demonstrated a 
typical diffusion-limited hypoxic pattern and showed a high degree of colocalization. 
Both MCT4 and CAIX showed a higher expression in the primary tumor in node positive 
patients (p = 0.09 both). 
Conclusion 
Colocalization and staining patterns of metabolic and hypoxia-related proteins provides 
valuable additional information over single protein analyses and can improve the under -
standing of their functions and environmental influences. 
70 | Chapter 4 Metabolic markers in relation to hypoxia | 71
in PBS) or donkey-anti-rabbitAlexa488 (1:600 in PBS) depending on the combination of 
markers stained in that tissue section. 
 Sections were incubated with rabbit-anti-GLUT-1 (Neomarkers, Fremont, CA, USA.), 
diluted 1:100 in PAD for 30 min at 37°C, followed by donkey-anti-rabbitAlexa488, 1:600 in 
PBS for 30 min at 37°C for detection of GLUT-1.
 Staining for HIF-1α was done by incubation with rabbit-anti-HIF-1α (Santa Cruz), 
diluted 1:50 in PAD overnight at 4°C, followed by goat-anti-rabbitCy3 (Jackson Immuno 
Research Laboratories Inc.), 1:600 in PBS for 30 min at 37°C. In the same section, all nuclei 
were stained with Hoechst (Sigma, Zwijndrecht), 0.33 µg/ml, in PBS for 5 min at room 
temperature.
 Finally, for detection of LDH-5 sections were incubated with sheep-anti-LDH-5 
(Abcam), diluted 1:100 in PAD overnight at 4°C. The next day, incubation with donkey-anti-
sheepCy3 (Jackson Immuno Research Laboratories Inc.), 1:600 in PBS for 30 min at 37°C, 
completed the staining.
 All sections were mounted in fluorostab (ProGen Biotechnik GmbH, Heidelberg, 
Germany).
Image acquisition and analysis
The tissue sections were scanned using a digital image processing system consisting of a 
high-resolution 12-bit CCD camera (Micromax, Roper Scientific Inc., Trenton, NJ, USA) on a 
fluorescence microscope (Axioskop, Zeiss, Göttingen, Germany) and a computer-
controlled motorised stepping stage. Image processing was done using IPLab software 
(Scanalytics Inc., Fairfax, VA, USA) on a Macintosh computer.17 Each tissue section was 
sequentially scanned for the three signals at 100x magnification with a resolution of 2.6 
µm / pixel. The resulting composite grey scale images were converted to binary images 
for further analysis. Thresholds for the fluorescent signals were interactively set above 
the background for each individual marker. The composite grey scale images were 
superimposed into one pseudocolored image for visual evaluation.
Guided by an H&E stained consecutive section, the tumor area of each section was 
delineated. This area was subsequently used as a mask in further analysis from which 
non-tumor tissue, large necrotic areas and artefacts were excluded. The marker fractions 
were defined as the tumor area positive for the marker, divided by the total tumor area. 
With this method, an automated quantitative analysis of the percentage of positively 
stained tumor tissue can be obtained. To determine the colocalization of the various 
markers with pimonidazole, the relative area positive within and outside the pimonidazole 
stained area was calculated.  Similar analyses were done to assess the colocalization 
between MCT1, MCT4, GLUT-1 and CAIX.
 The spatial distribution of the markers in relation to the blood vessels was measured 
by calculating the relative area positive in six zones around the closest vessels with a width 
related and metabolic markers in biopsies of head and neck tumors and in particular the 
association with pimonidazole as the reference exogenous hypoxic marker.15
Methods
Samples
The study was approved by the local ethics committee. 20 biopsies from 18 head and 
neck tumors were included in the analysis; from two tumors two biopsies were available. 
All patients received pimonidazole (1-((2-hydroxy-3-piperidinyl)propyl)-2-nitroimidazole 
hydrochloride, Hypoxyprobe-1; Natural Pharmacia International, Belmont, MA) intravenously 
(500mg/m2) two hours before biopsy taking. Pimonidazole is a bioreductive chemical 
probe that forms protein adducts in viable hypoxic cells. Biopsies were snap frozen in 
liquid nitrogen and stored until further processing. The samples were cut in sections of 
5µm and stained by immunofluorescence for pimonidazole, HIF-1α, CAIX, GLUT-1, LDH-5, 
MCT1, MCT4 and vessels in different combinations of 3 markers per tissue section.
Immunohistochemistry
For immunohistochemical processing, the sections were fixed for 10 minutes in acetone 
and rehydrated in PBS 0.1 mol/L (pH 7.4) (Klinipath, Duiven, The Netherlands). Between all 
consecutive steps of the staining procedure the sections were rinsed thrice for 5 minutes 
in PBS.
 For detection of pimonidazole, sections were incubated with rabbit-anti-pimo 
antibody (J.A. Raleigh, Department of Radiation Oncology and Toxicology, University of 
North Carolina, Chapel Hill, North Carolina, USA) diluted 1:1000 in primary antibody diluent 
(PAD, Abcam, Cambridge, UK) for 30 minutes at 37°C. The second incubation step was 
with donkey-anti-rabbit Alexa488 (Molecular Probes, Leiden, The Netherlands) diluted 
1:600 in PBS. Staining for vessels was done by incubation with the mouse antibody PAL-E 
(Euro Diagnostica, Arnhem, The Netherlands) diluted 1:10 in PAD, followed by incubation 
with chicken-anti-mouse Alexa647 (Molecular Probes) for 60 min at 37°C diluted 1:100 in 
PBS.
 The same secondary antibody (in a different tissue section) was used to detect CAIX, 
after incubation with mouse-anti-CAIX antibody (E. Oosterwijk, Department of Urology, 
University Medical Center, Nijmegen), diluted 1:25 in PAD for 30 min at 37°C.
 For detection of MCT1, sections were incubated with goat-anti-MCT1 (Santa Cruz)7, 
1:100 in PAD, overnight at 4°C. The next day the secondary antibody was added: donkey-
anti-goatCy3 (Jackson Immuno Research Laboratories Inc., West Grove, PA, USA) 1:600 in 
PBS, 30 min at 37°C.
 Staining for MCT4 was done by incubation with rabbit-anti-MCT4 (Santa Cruz)16, 1:100 
in PAD, overnight at 4°C. The secondary antibody was either goat-anti-rabbitFabCy3 (1:600 
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Extensive cytoplasmic LDH-5 expression was seen in most of the tumors (fraction range 
17 - 91%, median 37%, figure 2C), with more intense staining in hypoxic areas.
 Membranous CAIX expression closely followed the hypoxic pattern in some tumors, 
in others CAIX staining showed less spatial correlation with pimonidazole. The fraction 
ranged from 0 - 43% (median 4.7%) (Figure 2A, B and D).
of 50 µm each (0-50µm, 50-100µm, 100-150µm, 150-200µm, 200-250µm and>250µm).17 As 
the absolute fractions differ greatly, normalisation of fractions was performed for clear 
comparison of distributions. Quantitative analysis of the HIF-1α staining was not possible 
because of the low signal-to-background ratio in many HIF-1α-positive areas. All sections 
were visually scored by two observers and divided in two groups; high and low HIF-1α 
expression based on the intensity and the estimated fraction of HIF-1α positive cells. 
Differences between the observers were resolved at the microscope. 
Statistics
Statistical analyses were done with Prism software package for Macintosh. The relationships 
between metabolic parameters (as continuous variables) were tested using the Spearman 
rank correlation coefficient or the Pearson correlation coefficient as appropriate. Differences 
in colocalization were analyzed with a Mann-Whitney test. To test the association of the 
markers with categorical tumor characteristics (T-stage, N-stage and histopathological 
grade) either the Mann-Whitney test or Fisher’s exact test (after dichotomization of the 
variables) was used.
Results
20 biopsies of 18 patients with histologically confirmed advanced stage squamous cell 
carcinoma of the head and neck were included in this study. Tumor characteristics are 
shown in Table 1.
Correlation between metabolic markers and tumor characteristics
A trend to a higher expression of both MCT4 and CAIX in node positive patients was 
observed (p = 0.09 both) (Figure 1). After dichotomization of the variables MCT4 expression 
was significantly higher in node positive patients (p = 0.01). HIF-1α only showed a trend 
towards higher expression in node positive patients (p = 0.06), although HIF-1α expression 
was only found in one node negative tumor. In this biopsy the HIF-1α expression as well 
as the pimonidazole staining was found in well-differentiated areas around keratinization. 
T4 tumors showed a significantly lower pimonidazole staining (p = 0.02) and CAIX 
expression (p = 0.03) than T2 or T3 tumors. This inverse trend was found for MCT1 and 
MCT4 as well (p = 0.09 and p = 0.08 respectively). No correlations were found between any 
of the markers and differentiation grade.
Staining patterns
Examples of staining of all markers are shown in Figure 2. Pimonidazole fraction ranged 
from 0 - 34% (median 7%) and different hypoxic patterns were observed. Some tumors 
showed a typical ribbon-like pattern, others a more patchy pattern.18 (Figure 2A and B) 
Fig. 1  A significantly higher expression of MCT4 (p=0.04, a) and CAIX (p=0.05, b) was found in node- 
positive tumours. One tumor without nodal metastasis had a high CAIX expression of 17%. Interestingly, 
no HIF-1α expression was found in this tumor.
A B
Table 1  Tumour site, stage and grade
Characteristics Number
Tumour site
Larynx 7
Hypopharynx 4
Oropharynx 5
Oral cavity 2
T stage
T2 3
T3 6
T4 9
N stage
N0 6
N+ 12
Histopathological grade
Moderately differentiated 14
Poorly differentiated 4
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 MCT 1 showed a clear membranous staining pattern with substantial variation in 
intensity and extent; in some sections large MCT1 positive areas were seen, in other 
sections almost no MCT1 was present (fraction range 0.1 - 64%, median 14%). MCT1 
staining was not only observed adjacent to hypoxic areas, but also within hypoxic areas 
(Figure 2E). 
MCT4 showed a more diffuse staining pattern, with fractions varying from 0.6 - 49% 
(median 14%) and with more staining at increasing distance from the vessels. GLUT-1 had 
a comparable staining pattern to MCT4 (fraction range 3 - 43%, median 18%): diffuse 
staining throughout the tissue section, with more staining at increasing distance from the 
vessels. (Figure 2F and G) Apparent localised nuclear HIF-1α staining was present in 15 out 
of 20 biopsies, mostly in and around hypoxic areas (Figure 2H) with large variation in 
intensity. In some tissue sections membranous or cytoplasmatic staining was present as 
well, but only nuclear staining was taken into account.
Fig. 2  (A and B) Fluorescent microscopic images of two head and neck carcinomas with different 
pimonidazole (green) and CAIX (blue) staining patterns. 
(C – H) Examples of staining of the various markers. (C) LDH-5 (red), pimonidazole (green) and vessels 
(white). (D) Perinecrotic pimonidazole (green) and CAIX (red) staining, N = Necrosis. (E) MCT1 (red), 
pimonidazole (green) and vessels (white), note the co-staining of MCT1 with pimonidazole. (F and
G) Membranous GLUT-1 (F) and MCT4 (G) (both red) staining in relation to the vessels (white). 
(H) Nuclear HIF-1α (red) expression in relation to pimoniazole (green) staining. (I and J) Fluorescent 
microscopic images showing intense HIF-1α (red) staining in a pimonidazole-related (green) CAIX 
(blue) area and almost absent HIF-1α staining in another CAIX area in the same tissue section.
Fig. 3  Correlation between the six endogenous markers and pimonidazole with a schematic 
representation. Solid lines represent a significant correlation, dashed lines a trend (p-value between 
0.05-0.1).
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Correlations between markers
To get a global impression of the associations between the six markers overall correlations 
were calculated, irrespective of the geographical distribution. (Figure 3) The strongest 
correlation with pimonidazole was observed for LDH-5 fraction (r = 0.66, p = 0.002). CAIX 
showed significant correlations with MCT1, MCT4 and GLUT-1. 
 The expression of the endogenous markers was compared between biopsies with a 
high and low HIF-1α expression. (Figure 3) Overall, biopsies with a high HIF-1α expression 
demonstrated a significantly higher CAIX fraction. Remarkably, two biopsies clearly showed 
HIF-1α expression, but very low fractions of CAIX, GLUT-1 and MCT4. In one of the biopsies 
pimonidazole staining was associated with well-differentiated keratinizing areas as 
described by Janssen et al.,19 the other biopsy showed no pimonidazole staining at all. 
Overall, mean pimonidazole staining was equal in biopsies with high and low HIF-1α 
expression. A schematic representation of the associations between the markers is shown 
in Figure 3.
Colocalization of metabolic and hypoxic markers
The results of the quantitative analysis of the colocalization of the various markers are 
shown in Figure 4. MCT4 expression was significantly higher in hypoxic areas than in 
non-hypoxic areas (p = 0.001) and also clearly correlated to CAIX expression. GLUT-1 
expression and MCT4 expression showed an even stronger amount of colocalization with 
approximately six times higher GLUT-1 expression in MCT4 positive areas.
 MCT1 was present in well-oxygenated areas, but unexpectedly showed considerable 
expression in hypoxic areas as well (no significant difference, p = 0.11). Additionally, MCT1 
expression was significantly correlated with CAIX expression (p < 0.001). Pimonidazole 
stained areas exhibited, beside MCT4, a significantly higher expression of CAIX and LDH-5 
compared to pimonidazole negative areas.
 Although colocalization with HIF-1α expression could not be analyzed in the same 
manner as the other markers, it was observed that pimonidazole-related CAIX areas showed 
more intense HIF-1α expression than CAIX areas far from pimonidazole positive hypoxic 
areas (Figure 2 I and J).
Relationship of markers with vasculature
Chronic hypoxia is an important feature of malignant tumors, marked by a tissue oxygen 
gradient with lower oxygen tensions farther from the blood vessels. The expression of the 
endogenous markers in relation to the vessels, with pimonidazole as a reference hypoxic 
marker, can provide valuable information about their usefulness as a marker of chronic 
hypoxia. To assess the expression of the markers in relation to the vessels, fractions were 
calculated at different distances from the most nearby vessel in steps of 50 µm. In general, 
hypoxic fraction and LDH-5 staining increased at larger distances from the vessels. GLUT-1 
and MCT4 were present in variable fractions in the proximity of vessels, but the expression 
Fig. 4  Colocalization of the various markers. (A-D) CAIX, LDH and MCT4 show a significantly higher 
expression in pimonidazole stained areas, MCT1 expression is not significantly different. (E and F) 
Expression of MCT1 and MCT4 in CAIX negative and positive areas, both are significantly higher in 
areas expressing CAIX. (G and H) Increased expression of MCT1 and GLUT in MCT4 positive areas.
A B
C D
E F
G H
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 MCT1 expression clearly showed a different pattern compared to the other markers; 
in most tumors the MCT1 fraction increased slightly till 100 µm from the vessels and 
remained constant or modestly decreased again at larger distances. However, in the four 
tumors without hypoxia, MCT1 expression was present close to the vessels and decreased 
farther from the vessels.
Discussion
Hypoxia is an important feature of advanced head and neck tumors, with a negative 
influence on prognosis.12,20 Evaluation of cellular responses to hypoxia can be of clinical 
relevance in a prognostic and predictive way and possibly for treatment adaptation. Until 
now no endogenous marker has been found that strongly and consistently correlates 
with hypoxia, so different kind of analyses as presented here are crucial to elucidate the 
role of the various proteins and the response of tumor cells to a hypoxic microenvironment. 
 Although a global analysis of the overall expression of a certain protein allows easy 
comparison between biopsies and between different studies, it is a huge simplification of 
the true heterogeneous situation in a tumor biopsy. Therefore, to gain more insight in the 
spatial relationship between the metabolic markers and the oxygenation status in the 
tumor, we additionally assessed the expression of the proteins within and outside 
pimonidazole stained areas and the relation to the vessels. With this analysis more markers 
show an evident relationship with pimonidazole than with a global correlation analysis 
(Figure 4).
 Of the endogenous hypoxia-related markers that we examined, LDH-5 has the 
strongest relationship with pimonidazole. LDH-5 is one of the target enzymes of HIF-1 and 
has been described to have a strong association with HIF-1α expression in tumor tissue 
sections.21,22 The high expression of LDH-5 in hypoxic areas is as expected; it is one of the 
key enzymes in the glycolysis, the primary energy source in the absence of oxygen. The 
reason for a considerable expression of LDH-5 outside hypoxic areas could be the high 
rate of aerobe glycolysis (the Warburg effect) as often observed in malignant tumors4, 
although alternative explanations are possible, as pyruvate can originate from other 
pathways as well23. It should be noted that due to the similarity between LDH-5 and the 
other LDH isoforms, there is a possibility of some cross-reactivity of the antibody.
 CAIX is previously described to correlate weakly with pimonidazole binding.13,24,25 
Despite the weak overall correlation, CAIX fraction was significantly higher in the hypoxic 
(pimonidazole positive) areas. This emphasizes the strong association of this protein with 
hypoxia that could not be found by a simple correlation analysis. Interestingly, although all 
the endogenous markers, with the exception of MCT1, are regulated by HIF-19,10, the 
staining patterns and colocalization differ. An interesting observation is the strong 
resemblance of the HIF-1α and CAIX staining pattern (intermediate hypoxic areas). This 
increased about two to four-fold at > 150 µm from the vessels. All except four tumors 
exhibited this “chronic hypoxic pattern”. These remaining four showed no pimonidazole 
staining. Two examples of the distribution of the markers in tumors with pimonidazole 
(chronic hypoxic pattern) and without pimonidazole staining (non-hypoxic pattern) are 
shown in Figure 5. In one tumor (5a and b) with a large hypoxic fraction (20%) pimonidazole 
binding increases steeply with distance from the vessels. GLUT-1, MCT4 and LDH-5 follow 
this pattern but less steep, with a plateau reached between 150-200 mm. MCT1 expression 
increases until 150-200 mm and decreases at larger distances. In the second tumor (Figure 5c 
and d) all metabolic markers were strongly expressed without any relationship with the 
vessels and, in the absence of pimonidazole, not depending on hypoxia. Low HIF-1α and 
CAIX expression was present in this tumor.
Fig. 5  Marker expression in different zones around the vessels in a biopsy with a large hypoxic 
fraction (upper panels) and a tumor with no pimonidazole staining (lower panels). Pimonidazole 
staining increases steadily at larger distances from the vessels (A). The increase of GLUT, MCT4 and 
LDH expression is less steep with a plateau reached between 150-200 mm (B). MCT1 expression 
increases until 150-200 mm, a slight decrease is noted at larger distances (A). In the tumour with 
no pimonidazole staining, no increase of GLUT, MCT4 and LDH expression is observed (D) and a 
decrease in MCT1 expression at larger distances from the vessels (C).
A B
C D
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show good results with this antibody as well.7,36 As the fraction MCT1 even increased at 
larger distance from the vessels, it seems likely that MCT1, beside MCT4, plays a role in 
lactate export in hypoxic areas. It is reasonable to assume that in tumor cells, like in red 
blood cells, depending on the substrate concentrations and pH, MCT1 functions as either 
a lactate importer or assists MCT4 in lactate export.37 Either way, MCT1 has already shown 
some potential as a therapeutic target in vitro. Inhibition of MCT1 by lonidamine induced 
a strong decrease in intracellular pH and loss of viability of the tumor cells.34 The MCT1 
inhibitor α-cyano-4-hydroxycinnamate blocks lactate-fueled respiration in tumor cells 
and induces tumor growth retardation in a mouse model.6 Of interest is the strong 
correlation and colocalization of MCT1 with CAIX (Figure 3 and 4E), affirming an important 
role in pH regulation as described in melanoma and neuroblastoma.34,38
 In conclusion, metabolic markers show a strong but irregular relation with hypoxia 
with obvious correlations between markers, emphasizing the complex metabolic 
regulatory system with a strong environmental (hypoxia, pH) influence. Co-expression of 
markers provides additional information over single marker fractions. MCT4 and GLUT-1 
show a typical “diffusion-limited hypoxic” pattern with a strong colocalization indicating 
activation by similar stimuli. The positive correlation with N-stage makes MCT4 a potential 
marker for tumor aggressiveness, but its exact value still has to be established. MCT1 
overexpression is present in the majority of the advanced head and neck carcinomas in 
our series, in non-hypoxic as well as hypoxic areas. The strong colocalization with CAIX 
suggests an important role in pH regulation. 
Conclusion
Endogenous metabolic and hypoxia-related markers can be of great importance as 
prognostic and predictive markers and are potential therapeutic targets. As the various 
markers respond differently to hypoxia and other environmental factors, a combination of 
these markers could be used to predict treatment outcome and select the appropriate 
patients for new targeted therapies.
typical pattern circumferences the pimonidazole stained area with a partial overlap (Fig. 
2I). The colocalization of CAIX with HIF-1α is far from perfect, but more concordant than 
that of GLUT-1, MCT4 and LDH-5 with HIF-1α The strong relationship of CAIX with HIF-1 is 
known, with CAIX expression tightly controlled by HIF-1.26 In this context, an interesting 
observation is the higher level of HIF-1α expression in hypoxia-related CAIX areas than in 
CAIX areas separate from hypoxic (pimonidazole stained) areas (Figure 2I and J). A possible 
explanation of these findings could be the increased transcription of HIF-1α without 
stabilization in the intermediate hypoxic areas (areas with CAIX expression without HIF-1α 
staining) and stabilization of HIF-1α in severe hypoxic areas (areas overlapping and 
adjacent to pimonidazole with CAIX and HIF-1α staining).27 It could also indicate the 
transient presence of acute hypoxic areas, which are reoxygenated before pimonidazole 
administration. It was shown in SiHa (human cervical squamous cell carcinoma) tumors 
that up to 20% of the tumor cells were intermittently hypoxic over an 8-hour period.28 This 
explanation is less likely as CAIX upregulation requires a longer period of hypoxia.29 A third 
explanation could be the induction of HIF-1α and consequent activation of CAIX through 
a hypoxia-independent mechanism without stabilization of HIF-1α under these conditions. 
An acidic tumor microenvironment can influence HIF-1α and CAIX expression as well.29,30 
In any case, there is little evidence for a HIF-1 independent CAIX activating mechanism.26 
Most markers showed a range of co-expression, but a very strong spatial relationship was 
found between GLUT-1 and MCT4 (Figure 4H). These showed a comparable, typical 
expression increasing at larger distances from the vessels, with a two- to four-fold increase 
of the fraction at 150-200 µm. This pattern and agreement reflects their interrelated role in 
the glycolytic pathway under hypoxic conditions, GLUT-1 for glucose import and MCT4 for 
lactate export. LDH-5, one of the intermediary enzymes in this pathway, shows a similar 
pattern, but was not stained in the same section as MCT4 or GLUT-1, so the amount of 
colocalization could not be calculated. 
 Although a small series, a positive correlation between MCT4 and N-stage was found. 
Overexpression of MCT4 in malignancies has been described in colorectal cancer31 and 
cervical carcinomas32. Except for a trend towards shorter overall survival with MCT4 
positive adenosquamous carcinomas of the cervix, no correlations with clinicopathological 
data have been found before. These findings indicate that MCT4 is a potential marker for 
the aggressiveness of a tumor.
 MCT1 expression in > 5% of the tumor area was present in 14 of the 20 biopsies. MCT1 
expression in tumors has been described in lung cancer33, brain tumors34 and cervical 
cancer32. However, in the colonic epithelium, Lambert et al. found a decline in expression 
associated with transition to malignancy.35 In our study, MCT1 expression was present in 
oxic as well as hypoxic areas, in contrast to the observation made by Sonveaux et al. in 
biopsies of lung carcinomas6. It is important to note that in our study a different antibody 
was used of which some aspecificity formally can not be excluded, although other studies 
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Introduction
Over the years, the treatment for patients with advanced laryngeal cancer has shifted 
from laryngectomy to organ preservation strategies such as chemoradiation and 
radiotherapy with altered fractionation schedules. Still, a significant proportion of patients 
will undergo salvage laryngectomy and lose their natural voice or die from the disease 
due to locoregional recurrence or distant metastases. A current interest in clinical research 
is to identify biological treatment resistance mechanisms with the aim to deliver more 
effective and less toxic treatments. 
 An extensively studied adverse prognostic factor in solid tumors is hypoxia. Hypoxic 
tumors are more resistant to therapy and have a worse outcome compared to well-oxy-
genated tumors.1,2 Several exogenous and endogenous hypoxia markers have been 
studied to assess their value as quantitative measures of hypoxia as well as their prognostic 
potential.3 Endogenous markers can be assessed retrospectively on a large scale as 
opposed to exogenous markers, which have to be injected intravenously before taking a 
tumor sample. Here we studied carbonic anhydrase IX (CAIX), one of the targets of hypox-
ia-inducible-factor-1 (HIF-1). CAIX is involved in the respiratory gas exchange and acid-base 
balance and assists in maintaining intracellular pH under hypoxic conditions.4 In a number 
of studies CAIX has shown to be a prognostic marker and was associated with worse 
locoregional control and overall survival.4
 To specifically target hypoxic tumors, ARCON (accelerated radiotherapy with carbogen 
breathing and nicotinamide) was introduced in clinical studies in the early 1990s. ARCON 
combines radiotherapy with carbogen breathing and nicotinamide to counteract 
diffusion-limited and perfusion-limited hypoxia, respectively. From 2001 to 2008 a large 
randomized phase III trial in the Netherlands investigated accelerated radiotherapy (AR) 
versus ARCON in patients with advanced carcinoma of the larynx.5 The biopsy material 
from the patients in that trial has been used for the current study with the objective to 
assess the prognostic and predictive value of CAIX with respect to AR and ARCON.
Material and methods
Patients
In the ARCON phase III trial 345 patients with advanced laryngeal cancer were randomized 
between AR and ARCON from 2001 to 2008. Inclusion criteria were: histological 
confirmation of squamous cell carcinoma of the larynx, stage T2b-T4, all N-stages, no 
distant metastasis, WHO performance status 0-1, age > 18 years, and written informed 
consent. Radiotherapy in the experimental arm was combined with carbogen (98% O2 
and 2% CO2) breathing and nicotinamide (60 mg/kg orally) administration 1-1.5 h before 
treatment.
Abstract
Purpose 
In a phase III trial in patients with advanced stage laryngeal carcinoma comparing ARCON 
(accelerated radiotherapy with carbogen breathing and nicotinamide) to accelerated 
radiotherapy alone (AR) the prognostic and predictive value of CAIX, a hypoxia-associated 
protein, was investigated. 
Methods 
261 paraffin embedded tumor biopsies and 79 fresh frozen biopsies from patients entered 
in the trial were immunohistochemically stained for CAIX. CAIX-fraction and CAIX 
expression pattern were related to tumor control and patient survival.
Results 
Low CAIX-fraction was prognostic for worse regional control and overall survival in 
patients treated with AR. Patients with a low CAIX-fraction treated with ARCON had better 
regional control and metastasis-free survival compared to AR (RC 97% vs 71%, p<0.01 and 
MFS 92% vs 69%, p=0.06).
 Patients with a perinecrotic CAIX staining pattern had a significantly worse local 
control, metastasis-free and overall survival compared to patients with a diffuse pattern 
(65% vs 84%, p=0.01, 70% vs 96%, p<0.01 and 42% vs 71%, p<0.01 respectively), and this 
could not be improved with ARCON. After multivariate analysis CAIX pattern and N-stage 
emerged as significant predictors for metastasis-free survival and overall survival.
Conclusion 
ARCON improves regional control and metastasis-free survival only in patients with low 
CAIX expression. The different patterns of CAIX expression suggest different mechanisms 
of upregulation and have important prognostic value.
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 The frozen tissue sections were scanned at 100x magnification using a digital image 
processing system consisting of a high-resolution 12-bit CCD camera (Micromax, Roper 
Scientific Inc., Trenton, NJ, USA) on a fluorescence microscope (Axioskop, Zeiss, Göttingen, 
Germany) and a computer-controlled motorized stepping stage. 8 Image processing was 
done using IPLab software (Scanalytics Inc., Fairfax, VA, USA) on a Macintosh computer. 
The resulting composite grayscale images were converted to binary images for further 
analysis. For this conversion, thresholds for the fluorescent signals were interactively set 
above the background staining. The CAIX fraction was defined as the tumor area positive 
for CAIX, divided by the total tumor area. The vascular parameters VD (vessel density) and 
RVA (relative vascular area) were defined as the number of vessels per square mm and the 
vascular area divided by the  tumor area, respectively.
Statistics
Statistical analyses were performed on a Macintosh computer using Prism 4.0 (Hearne 
Scientific software, Dublin, Ireland) software package. 
 Correlations between CAIX fraction and tumor characteristics were tested with the 
Kruskal-Wallis test, or the Mann-Whitney test in case of only two subgroups. To test for 
differences in tumor characteristics between treatment groups the chi-square or Fisher’s 
exact test (as appropriate) were applied. For survival analysis, patients were dichotomized 
by the median value of CAIX fraction and classified according to the expression pattern. 
Endpoints were 5-year local control, regional control, metastasis-free survival and overall 
survival. Univariate and multivariate Cox regression analyses were performed to evaluate 
the prognostic value of the different parameters. P-values <0.05 were considered significant.
Results
Paraffin embedded biopsy material could be retrieved from 303 patients. 42 biopsies were 
excluded because of the absence of invasive carcinoma or poor quality of the sample. In 
total, 261 biopsies were available for analysis. Patient and tumor characteristics are 
summarized in Table 1. There were no differences between the two treatment arms.
Different patterns of CAIX staining could be observed (Figure 1); a typical perinecrotic pattern, 
as descibed earlier by Beasley et al.9, and a more diffuse staining pattern, unrelated 
to necrosis. In 187 biopsies a sufficient amount of CAIX staining was present to assess the 
pattern, 42 of these showing the perinecrotic pattern and 145 biopsies the diffuse pattern. 
The CAIX fraction defined as percentage of the total tumor area was similar for both 
patterns (mean 36% versus 39%, p=0.75). In 74 patients the CAIX expression was too low 
to recognize a pattern. Overall, the CAIX fraction varied from 0–93% (median value 22%).
 Biopsy material obtained for routine purposes of 303 of these patients was retrieved 
from 37 pathology departments in the Netherlands. The biopsies had been fixed in 
formaldehyde and were paraffin-embedded. 
 Additionally, from 79 patients fresh frozen biopsies were obtained 2 h after injection 
of the nitroimidazole hypoxia marker pimonidazole. Seventy of these patients are included 
in both analyses as paraffin material was present as well.
Besides for validation of the results by different staining and analysis techniques, these 
frozen samples were also used to study the relation of CAIX with pimonidazole, vascular 
density (VD) and the relative vascular area (RVA). Frozen tissue sections are better suited for 
staining and analysis of multiple markers.
Immunohistochemistry
All samples were cut in sections of 5 µm. One section was stained for haematoxylin and 
eosin to distinguish tumor from non-tumor tissue.
 Paraffin-embedded sections were immunohistochemically stained for CAIX as described 
earlier.6 Mouse-anti-CAIX (E. Oosterwijk, department of Urology, Radboud University 
Nijmegen Medical Centre) was used as the primary antibody and biotin-labelled-F(ab’)2-
donkey-anti-mouse IgG (Jackson Immunoresearch Laboratories, West Grove, PA, USA) was 
applied as the secundary antibody. A negative control without the primary antibody was 
included.
 From the frozen biopsy material, sections of 5 μm were cut and mounted on 
poly-l-lysine coated slides and stored at −80 °C. For detection of CAIX, the sections were 
incubated with mouse-anti-CA-IX antibody (E. Oosterwijk).7 The second incubation was 
with goat-anti-mouse (Fab) Cy3 antibody (Jackson Immunoresearch Laboratories) The 
vessels were stained by incubation with the mouse antibody PAL-E (Euro Diagnostica, 
Arnhem, the Netherlands), followed by incubation with chicken-anti-mouse Alexa467 
antibody (Molecular Probes Inc., Eugene, OR, USA). 
Image analysis
For analysis of the paraffin-embedded biopsies a digital image processing system for 
quantitative analysis of immunohistochemically stained sections using bright field 
microscopy was used, as described earlier.6 Whole tumor sections were scanned with a 10x 
objective at 100x magnification using a Macintosh computer running IPLab for Macintosh 
(Scanalytics Inc., Fairfax, VA, USA) resulting in RGB color composite images. Haematoxylin/
eosin stained sections were used as a guide to manually delineate the tumor area, excluding 
normal tissue, necrotic areas and artefacts, creating a mask for image analysis. 
 After subtraction of a background image, the individual colours from the DAB (brown) 
and haematoxylin (blue) signals were separated, resulting in grayscale images for each 
color. For further processing, a threshold for each signal was interactively set and the area 
positive for CAIX was calculated by parametric mapping as published previously.6 
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Fresh frozen material was obtained from 79 patients (Table 1). The CAIX fraction varied 
from 0 - 26% with a median value of 0.9%. A significant correlation was observed between 
CAIX fraction in paraffin-embedded and fresh frozen biopsies (r = 0.45, p<0.001). Note that 
paraffin-embedded tissue and frozen material were processed by different staining 
techniques and analysis methods. 
Outcome – paraffin embedded samples
No correlation was observed between CAIX fraction and tumor characteristics like T-stage, 
N-stage and differentiation grade.
 When using the median value as a cut-off, in the group of patients treated with AR 
there was a trend to a worse regional control and overall survival in patients with a tumor 
with a low CAIX fraction compared to patients with a tumor with a high CAIX fraction 
(77% vs 91%, p = 0.09 and 48% vs 67%, p = 0.09 respectively, Figure 2). Patients with a low 
CAIX fraction treated by ARCON had a higher regional control (93% vs 77%, p = 0.03) and, 
although it did not reach statistical significance, metastasis-free survival (92% vs 79%, p = 
0.12) than those treated by AR. In patients with a high CAIX fraction, there was no difference 
between treatment with ARCON and AR (regional control 95% vs 91%, p = 0.30 and metas-
tasis-free survival 91% vs 87%, p = 0.45).
Outcome - fresh frozen material
The analysis of the frozen material confirmed the results obtained with the paraffin 
biopsies: improved regional control and metastasis-free survival with ARCON in patients 
with a low CAIX fraction (100% vs 79%, p = 0.07 and 100% vs 67%, p = 0.02, respectively). 
Also in this analysis no differences between the two treatments were observed in patients 
with a high CAIX fraction.
Staining patterns
The patients with a tumor with a perinecrotic pattern had a significantly worse local 
control, metastasis-free survival and overall survival (65% vs 84%, p = 0.01, 70% vs 96%, 
p < 0.01 and 42% vs 71%, p < 0.01 respectively, Figure 3) compared to the diffuse CAIX 
pattern. ARCON was not able to improve outcome for these patients. Consistent with the 
results after dichotomization by the median, the gain of ARCON over AR was predominantly 
seen in the group with no or very low CAIX expression and no recognizable pattern 
(regional control 97% vs 71%, p = 0.01 and metastasis-free survival 92% vs 69%, p = 0.06, 
Figure 4). Tumors with a low CAIX expression or perinecrotic pattern were more often 
poorly differentiated compared to the diffusely CAIX expressing tumors (p = 0.04), which 
often showed expression associated with keratinizing, well-differentiated areas. 
Furthermore, the percentage of tumors exhibiting a diffuse staining pattern was higher in 
glottic compared to supraglottic tumors, while a perinecrotic pattern was observed more 
often in supraglottic tumors (64% vs 49% and 21% vs 9% respectively, p = 0.02). 
Fig 2. Kaplan-Meier survival curves based on analysis of 261 paraffin embedded tumor biopsies showing worse 
regional control (B) and overall survival (D) in patients with a tumor with low expression of CAIX, treated with 
radiotherapy alone. No difference was observed for local control (A) and metastasis-free survival (C).
Table 1  Patient and tumor characteristics.
Paraffin (261) Fresh frozen (79)
ARCON( 130) AR(131) ARCON(40) AR(39)
sex
 male 109 (84) 101 (77) 27 (68) 27 (69)
 female 21 (16) 30 (23) 13 (32) 12 (31)
Median age (range) 62 (43-84) 61 (38-88) 61 (46-83) 60 (38-81)
T stage
 T2 42 (32) 52 (40) 5 (13)* 12 (31)
 T3 72 (56) 58 (44) 30 (75) 20 (51)
 T4 16 (12) 21 (16) 5 (13) 7 (18)
N stage
 N0 83 (64) 84 (64) 19 (48) 18 (46)
 N+ 46 (36) 47 (36) 21 (52) 21 (54)
site
 glottic 56 (43) 51 (39) 13 (33) 12 (31)
 supraglottic 74 (57) 80 (61) 27 (67) 25 (64)
 sub / transglottic 2 (5)
Differentiation grade
 well 9 (7) 9 (7) 2 (5) 4 (10)
 moderately 77 (59) 72 (55) 23 (57) 23 (59)
 poor 25 (19) 18 (14) 15 (38) 7 (18)
 unknown 19 (15) 32 (24) 5 (13)
Fraction CAIX
 high 67 (52) 65 (50) 20 (50) 18 (46)
 low 63 (48) 66 (50) 20 (50) 21 (54)
CAIX pattern
 Diffuse 73 (56) 72 (55)
 Perinecrotic 20 (15) 22 (17)
 No pattern 37 (28) 37 (28)
* p = 0.07 distribution of T-stage in ARCON arm vs AR
ARCON = accelerated radiotherapy with carbogen and nicotinamide, AR = accelerated radiotherapy
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Univariate analysis including CAIX fraction, CAIX pattern, T-stage, N-stage, differentiation 
grade, treatment arm and differentiation grade revealed N-stage, CAIX pattern and tumor 
site as the most important prognostic factors for metastasis-free survival and N-stage and 
CAIX pattern for overall survival (Table 2). In a multivariate analysis including all significant 
parameters, CAIX pattern and N-stage emerged as the only significant predictors for 
 metastasis-free survival (Table 3).
Fig. 1  Two examples of paraffin embedded biopsies, immunohistochemically stained for CAIX, 
showing a typical perinecrotic staining pattern (A) and a diffuse pattern (B).
A B
Fig. 2  Kaplan-Meier survival curves based on analysis of 261 paraffin embedded tumor biopsies 
showing worse regional control (B) and overall survival (D) in patients with a tumor with low 
expression of CAIX, treated with radiotherapy alone. No difference was observed for local control (A) 
and metastasis-free survival (C).
A B
C D
N o at risk:
High CAIX 65 55 47 42 30 23 17
Low CAIX 66 61 49 42 25 22 15
N o at risk:
High CAIX 65 59 54 50 36 29 21
Low CAIX 66 59 48 41 22 19 14
N o at risk:
High CAIX 65 62 56 51 38 29 22
Low CAIX 66 62 53 41 25 23 16
N o at risk:
High CAIX 65 64 57 53 39 30 22
Low CAIX 66 63 54 45 26 23 16
Fig. 3  Kaplan-Meier survival curves based on 261 paraffin embedded biopsies showing worse 
local control (A) metastasis-free survival (C) and overall survival (D) for patients with a tumor with 
a perinecrotic CAIX staining pattern compared to a diffuse pattern, irrespective of treatment. No 
prognostic value was seen for regional control (B). P-values refer to the difference between the 
perinecrotic expression pattern and diffuse expression pattern.
A
p = 0.01
B
p = 0.36
D
p < 0.01
C
p < 0.01
N o at risk:
Low CAIX 74 68 55 47 31 28 20
Perinecrotic 42 32 25 17 15 12 9
Diffuse 145 127 113 99 79 66 50
No at risk:
Low CAIX 74 68 54 47 29 26 20
Perinecrotic 42 37 30 23 19 15 11
Diffuse 145 129 120 106 86 74 55
No at risk:
Low CAIX 74 70 59 52 34 30 22
Perinecrotic 42 39 30 23 19 15 11
Diffuse 145 135 126 110 89 75 56
No at risk:
Low CAIX 74 69 56 47 33 30 22
Perinecrotic 42 36 28 21 17 14 11
Diffuse 145 134 125 109 89 75 56
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Correlation with pimonidazole and vascular parameters
A significant, but weak correlation was observed between the CAIX fraction and the 
hypoxic fraction as assessed by pimonidazole staining (r = 0.36, p < 0.01, Figure 5), which 
has a predominant diffusion-limited staining pattern. No correlation was observed with 
VD (r = -0.06, p = 0.59), but a significant weak negative correlation was present with the 
RVA (r = -0.39, p < 0.01).
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Fig. 4  Kaplan-Meier survival curves based on 74 paraffin embedded tumor biopsies with no 
recognizable pattern (no or very low CAIX expression) showing improved regional control (A) and 
metastasis-free survival (B) with ARCON.
A B
N o at risk:
ARCON 37 34 29 25 18 17 13
Acc RT 37 35 26 23 12 10 8
N o at risk:
ARCON 37 34 28 25 19 17 13
Acc RT 37 36 29 23 15 14 10
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Discussion
In this study we investigated the prognostic and predictive value of CAIX in patients with 
advanced laryngeal cancer treated in the ARCON randomised trial. Two datasets were 
used: one based on paraffin-embedded immunohistochemically stained biopsies taken 
for diagnostic purposes and a dataset based on additional fresh frozen biopsies obtained 
after injection of the hypoxia marker pimonidazole and stained with immunofluorescence. 
In the latter dataset multiple stainings per tissue section were performed to assess the 
correlation of CAIX with pimonidazole and vascular parameters. Furthermore, it provided 
a confirmation of the results obtained with the paraffin dataset. 
 Although the associations with outcome were comparable in the two datasets, the 
absolute values of the CAIX fraction largely differ for two reasons. The first is the difference 
in detection sensitivity between the two staining methods. The ABC-staining method, 
used on the paraffin biopsies, has a greater sensitivity, as the signal is largely enhanced by 
the avidin-biotinylated enzyme complexes. Secondly and more important, the method of 
analysis is different (parametric mapping versus binary analysis, see materials and methods 
section), resulting in larger fractions for the paraffin material. 
 Our data show predictive potential of CAIX in both datasets; regional control and 
metastasis-free survival was worse in patients with a low CAIX expression and this was 
corrected by ARCON. This may be somewhat counter-intuitive, because a higher CAIX 
expression is generally associated with hypoxia via HIF-1α and ARCON aims to counteract 
hypoxia.5 Nevertheless, the current results are in concordance with results from a previous 
cohort of advanced head and neck cancer patients treated with ARCON.10 
 Although CAIX is often considered a hypoxia-associated marker, it has not shown to 
be very robust for quantifying clinically relevant hypoxia. The correlation with oxygen 
electrode measurements and exogenic hypoxic markers, like pimonidazole and EF-5, is 
weak as demonstrated in the current investigation as well as in other reports.2,11-14 Studies 
investigating the prognostic value of CAIX have shown equivocal results, some 
demonstrating a negative correlation with outcome and others a positive or no correlation 
at all.12,15-20 
 Because of these inconsistencies we looked further into the patterns of CAIX 
expression as we observed striking differences in staining patterns between tumors. 
Three distinct types were identified: a perinecrotic pattern, a diffuse pattern and a 
remaining group without a  recognizable pattern (very low CAIX expression). The typical 
perinecrotic pattern for CAIX has been described before in breast cancer and head and 
neck cancer as the dominant expression pattern and is generally associated with chronic 
or diffusion-limited hypoxia.21,22 In the current dataset only 17% of the tumors showed this 
perinecrotic pattern. The diffuse CAIX expression pattern has been described earlier in 
VHL-defective renal cell carcinomas.23 Patients with a tumor showing the perinecrotic 
pattern had a significantly worse outcome, while the diffuse pattern indicated a good 
Table 3  Multivariate Cox regression analysis
Metastasis-free survival Overall survival
HR 95% CI p HR 95% CI p
CAIX pattern diffuse 1.0 1.0
no pattern 4.6 1.7-12.2 0.002 1.7 1.1-2.7 0.03
perinecrotic 7.2 2.6-19.9 <0.001 2.5 1.5-4.1 0.001
Tumor site glottic 1.0
supraglottic 0.8 0.3-2.2 0.69
N-stage N0 1.0 1.0
N+ 4.0 1.7-9.8 0.002 1.6 1.1-2.4 0.02
Fig. 5  (A) Correlation between pimonidazole hypoxic fraction and CAIX expression in 79 fresh 
frozen tumor biopsies (r = 0.36, p < 0.01). Linear best fit is shown. Datapoints (2,26) and (19,20) have 
been relocated in the graph to enhance visuality. Fluorescent microscopic image of a laryngeal 
carcinoma with a high (B) and low (C) degree of colocalization between pimonidazole (green) and 
CAIX (red).
A
B C
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 Interestingly, studies investigating HIF-1α have found the same prognostic value of 
the pattern of marker expression. A perinecrotic HIF-1α expression was a negative 
prognostic factor compared to a diffuse pattern in studies in breast cancer and endometrial 
carcinoma21,35 and regarded as a sign of tumor agressiveness.
Conclusion
ARCON improves regional control and metastasis-free survival in patients with a larynx 
carcinoma with low expression of CAIX. A diffuse CAIX staining pattern is associated with 
tumor differentiation and better outcome results. A perinecrotic CAIX pattern is indicative 
for an agressive phenotype with high risk of metastasis formation, that cannot be 
counteracted with ARCON treatment.
prognosis, suggesting a different biology and function of CAIX in these tumors. It should 
be noted that the overall amount of CAIX expression was not different between the two 
expression patterns. These distinct patterns have not been considered in most other 
studies, which could explain the contradictory results with respect to the prognostic 
value of CAIX. In renal cell carcinoma, which mostly show a diffuse pattern, CAIX has been 
found to be a positive prognostic factor as well.24,25
 The different patterns could be the result of different mechanisms of upregulation of 
CAIX. The best known trigger for CAIX upregulation is through HIF-1α stabilization by 
hypoxia, which can be expected to play an important role in the perinecrotic expression 
pattern. Pathways or factors other than hypoxia can be involved in HIF-1α stabilization and 
CAIX upregulation in normoxic circumstances. These include the PI3-K pathway 26, acidosis 
27,28 and genetic alterations like in renal cell carcinomas. VHL or p53 mutations can inhibit 
the degradation of HIF-1α 29,30, which, upon stabilization, stimulates expression of CAIX. 
These explanations for the more diffuse, hypoxia-independent, staining pattern do not 
necessarily imply a worse prognosis with higher CAIX expression. 
Furthermore, this study comprises only a distinct subgroup of all head and neck cancers 
i.e. laryngeal carcinoma. Etiological factors differ between the specific head and neck 
subsites.31,32 Previous investigations showed that laryngeal carcinomas harbour a restricted 
spectrum of p53 mutations 33 and are often more well differentiated than other head and 
neck subsites. Such differences can have major impact on the expression of tumor markers 
and the response to therapy. 
 The correlation with differentiation grade, with well-differentiated keratinizing tumors 
exhibiting more often a diffuse pattern and high grade tumors a low CAIX expression or 
perinecrotic pattern leads to another hypothesis. Well-differentiated tumors could be 
expressing CAIX as a physiological reaction to an altered microenvironment (changes in 
pH due to rapid tumor growth and altered metabolism for example). The loss of this 
reactive diffuse CAIX expression in tumors with low or perinecrotic CAIX expression could 
be a sign of dedifferentiation and more aggressive behavior including metastasis 
formation. However, only in the low CAIX tumors this can be counteracted by ARCON. This 
indicates that perinecrotic CAIX signifies an aggressive tumor phenotype and that this 
aggressiveness may not necessarily be related to hypoxia. Furthermore, it can be 
concluded that absence of CAIX does not implicate absence of hypoxia. This is supported 
by only a weak correlation between CAIX expression and pimonidazole binding and the 
ability of ARCON to improve outcome in tumors with low CAIX expression.
 Another study employing hypoxic (radio)sensitisation using the nitroimidazole 
compound nimorazole  showed no predictive value of CAIX.34 However, different subsites 
of head and neck cancer were included in that study, the pattern of CAIX expression was 
not assessed and the mechanism of action of nimorazole differs from that of ARCON 
which may all be explanations for the discrepancy with the current study.
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Background
Early stages of laryngeal cancer can, in most cases, be cured with laser surgery or 
radiotherapy alone. For the more advanced stages, radiotherapy is the treatment of choice 
either or not combined with chemotherapy, but targeted therapies and  hypoxia-
modifying treatments are applied as well. Given that only a minority of the patients profits 
from these modifications, research efforts should focus on biology-based selection of 
patients for the most effective treatment and least burden.
 A well-known adverse prognostic factor in all types of cancer is proliferation. A meta- 
analysis showed a correlation of high proliferation index with low survival in head and 
neck cancer, albeit individual studies show equivocal results.1 A widely used immuno-
histochemical proliferation marker is Ki-67. This endogenous marker is expressed in all 
phases of the cell cycle, with exception of the G0 phase and is thought to represent the 
growth fraction of the tumor.
 Another extensively studied adverse prognostic factor is hypoxia. Hypoxic tumors are 
more resistant to therapy and have a worse outcome compared to well-oxygenated 
tumors.2,3 In theory, hypoxic cells that have retained their proliferative capacity could be 
the cause of persistent or recurrent disease. A previous study showed the presence of 
such a subpopulation of tumor cells and its correlation with disease-free survival.4 
 To specifically target both proliferation and hypoxic radioresistance, ARCON (accelerated 
radiotherapy with carbogen breathing and nicotinamide) treatment was introduced, 
which combines accelerated radiotherapy with carbogen breathing and nicotinamide. 
A randomized phase III trial in the Netherlands in 345 patients with advanced carcinoma 
of the larynx showed increased regional control with ARCON.5 In the current study, the 
biopsy material from these patients has been used to assess the prognostic value of Ki-67 
either as a single marker or combined with the hypoxia-associated marker carbonic 
anhydrase IX (CAIX) and the response to ARCON therapy.
Materials and methods
Patients
In the ARCON phase III trial 345 patients with advanced laryngeal cancer were randomized 
between accelerated radiotherapy (AR) and ARCON from 2001 to 2008. Inclusion criteria 
were: histological confirmation of squamous cell carcinoma of the larynx, stage T2b-T4, all 
N-stages, no distant metastasis, WHO performance status 0-1, age > 18 years, and written 
informed consent. Radiotherapy in the experimental arm was combined with carbogen 
(98% O2 and 2% CO2) breathing and nicotinamide (60 mg/kg orally) administration 1-1.5 h 
before treatment. Biopsy material obtained for routine purposes of 303 of these patients 
was retrieved from 37 pathology departments in the Netherlands. The biopsies had been 
Abstract
Purpose 
The prognostic and predictive value of the proliferation marker Ki-67 was investigated in 
a phase III trial in patients with T2-4 laryngeal carcinoma comparing ARCON (accelerated 
radiotherapy with carbogen breathing and nicotinamide) to accelerated radiotherapy 
alone (AR).
Methods 
Tumor biopsies from 255 patients were immunohistochemically stained for Ki-67 and the 
hypoxia-related marker CAIX. Labeling index of Ki-67 (Ki-67-LI) and the colocalization with 
CAIX was related to tumor control and patient survival.
Results 
On average, node positive patients had a higher Ki-67-LI compared to node negative 
patients (median 14% vs 8% p < 0.01). In the cohort treated with AR alone  high Ki-67-LI 
(>10%) was associated with increased regional and distant metastases formation.  This was 
not observed in the patients treated with ARCON. Regional- and distant metastases-free 
survival were 79% vs 96%, p < 0.01 and 71% vs 88% p = 0.05, for AR and ARCON, respectively. 
Local control and disease-specific survival were not significantly different between the 
treatment arms (78% vs 80%, p = 0.91 and 70% vs 76%, p = 0.53). Patients with low Ki-67 
expression had an excellent outcome with accelerated radiotherapy and this could not be 
further improved with ARCON. Colocalization of Ki-67 with CAIX provided no additional 
prognostic information.
Conclusion 
Patients with larynx carcinomas with high proliferative activity are at increased risk of 
regional and distant metastases formation. This risk can be reduced by treatment with 
ARCON.
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Statistics
Statistical analyses were performed on a Macintosh computer using Prism 4.0 (Hearne 
Scientific software, Dublin, Ireland) software package. Differences between tumor 
characteristics and markers were tested with the Mann-Whitney test or in case of multiple 
groups the Kruskal-Wallis test. Correlations between markers were calculated using the 
Spearman rank correlation test. For survival analysis marker parameters were dichotomized 
based on the median value. Local control (LC), regional control (RC), metastasis-free 
survival (MFS) and disease-specific survival (DSS) were estimated using the Kaplan-Meier 
method and compared with the log-rank test. Multivariate analysis was performed using 
the Cox proportional hazards model. P-values < 0.05 were considered significant.
Results
From the 303 paraffin biopsies, 255 biopsies were suitable for analysis. 48 biopsies were 
excluded for various reasons: no or very scarce tumor tissue in the biopsy, tissue section 
damaged during staining procedure or poor staining quality. Tabel 1 shows the patient 
and tumor characteristics. The median Ki-67-LI was 10% with a range of 0 - 44%. Examples 
of the staining are shown in Figure 1.
 Colocalization of Ki-67 with CAIX varied from 0 – 100% (FCAIX[Ki-67]) and 0 - 71% 
(FKi-67[CAIX]) and correlated very strong with the single marker expression (FCAIX[Ki-67] vs 
Ki-67-LI r = 0.82, p < 0.01 and FKi-67[CAIX] vs fraction CAIX r = 0.87, p < 0.01).
fixed in formaldehyde and paraffin-embedded. All samples were cut in sections of 5 µm. One 
section was stained for haematoxylin and eosin as a guide to delineate the tumor area.
Immunohistochemistry
Paraffin sections were deparaffinized in Histosafe (clearing agent, Adamas, the 
Netherlands), rehydrated through a graded ethanol series and boiled for 30 minutes in 
antigen retrieval solution. After cooling for 25 minutes and rinsing in PBS, endogenous 
peroxidase was blocked with 3% H2O2 in methanol. Then, sections were incubated with 
5% normal donkey serum in PAD (primary antibody diluent, Abcam, UK) to block non- 
specific binding.
 Sections were incubated at 4 °C overnight with rabbit anti-human Ki-67 (Abcam, UK) 
diluted 1:50 in PAD. Subsequently, the biotinylated secondary antibody was applied; 
biotin-labelled-F(ab’)2-donkey anti-rabbit IgG (Jackson Immuno Research), followed by 
ABC-reagent (Vector Elite kit, Vector Laboratories) for 30 minutes. 
 For the detection of CAIX, consecutive sections were incubated at 4 °C overnight 
with mouse anti-CAIX (E. Oosterwijk, department of Urology, Radboud University 
Nijmegen Medical Centre) diluted 1:25 in PAD, followed by labeling with biotin-labelled-
F(ab’)2-donkey anti-mouse IgG (Jackson Immuno Research) as a secondary antibody and 
ABC-reagent (Vector Elite kit, Vector Laboratories) for 30 minutes.
 Peroxidase activity was detected with diaminobenzidine (DAB). Finally, sections were 
counterstained with haematoxylin for 30 seconds and mounted with KP mounting 
medium (Klinipath, Duiven, the Netherlands). For negative controls, PAD was added 
without the primary antibody.
Image processing
Whole tumor sections of the paraffin-embedded biopsies were scanned and analyzed by 
parametric mapping as described before.6 With this method, besides analysis of single 
markers, colocalization of multiple markers in different subcellular compartments can be 
assessed. In short, a mosaic image of a whole tumor section is subdivided in squares of 36 
x 36 µm. For each square the labeling index of Ki-67 was determined and set as a new 
value in the resulting parameter image map. This value was compared with the value of 
the corresponding square in the CAIX parameter image map, that was labeled positive or 
negative for CAIX.
 The labeling index of Ki-67 (Ki-67-LI) was calculated as well as the area positive for 
CAIX relative to the total tumor area (fraction CAIX). The colocalization of Ki-67 with CAIX 
was assessed using two parameters: FCAIX[Ki-67] (Fraction of area positive for CAIX and for 
Ki-67 relative to total area positive for CAIX) and FKi-67[CAIX] (Fraction of area positive for 
CAIX and for Ki-67 relative tot total area positive for Ki-67).
 The pattern of CAIX staining was visually scored, distinguishing a perinecrotic pattern, 
a diffuse pattern or no recognizable pattern due to very low CAIX expression.
Fig. 1  Examples of immunohistochemical staining for Ki-67 expression with a haematoxylin 
counterstain. Tumor with a low Ki-67 labeling index (8%; A) and a high Ki-67 labeling index (17%; B). 
Scalebars: 100 mm.
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Associations with treatment outcome
With accelerated radiotherapy alone, patients with a high Ki-67-LI (>10%) had a worse RC 
(79% vs 91%, p = 0.08), MFS (71% vs 96%, p < 0.01) and DSS (70% vs 89%, p < 0.01, Fig. 3) 
compared to those with a low Ki-67-LI. In patients with high Ki-67-LI RC was significantly 
better with ARCON compared to AR (96% vs 79%, p < 0.01, Fig. 4) and an improvement in 
MFS was observed as well (88% vs 71% p = 0.05). ARCON had no effect on LC and DSS (80% 
vs 78%, p = 0.91 and 76% vs 70%, p = 0.53 for ARCON vs AR, respectively). Patients with low 
Ki-67 expression had an excellent outcome irrespective of the treatment arm (Figure 3 and 
4). In the subgroup of patients with no nodal metastasis at diagnosis (N0), predictive value 
of Ki-67-LI was maintained for regional control (ARCON 100% vs AR 85%, p = 0.04).
 Table 2 shows the results of the univariate analysis separate for both treatment arms. 
In a multivariate analysis including Ki-67-LI and N-stage, Ki-67-LI lost its trend to significance 
with respect to regional control. However, the effect on MFS remained significant for 
N-stage as well as for Ki-67-LI. Both parameters showed a trend to significance for DSS 
(p = 0.06 and p = 0.05 respectively) in multivariate analysis.
 The results obtained with Ki-67 / CAIX colocalization parameters were similar to the 
single marker analysis and provided no additional prognostic information. 
Correlation with clinicopathological characteristics
On average, node positive patients had a significantly higher Ki-67-LI than node negative 
patients (median 14% vs 8% p < 0.01, Figure 2). Higher T-stage was associated with a 
slightly higher Ki-67-LI (7% for T2 and 11% for T3/4, p = 0.09). 
 Ki-67-LI was not correlated with fraction CAIX (r = 0.10, p = 0.14). Ki-67-LI of tumors 
with a perinecrotic CAIX staining pattern was higher compared to tumors with a diffuse 
CAIX staining pattern (median 14% vs 9%, p = 0.02). 
Table 1  Patient and tumor characteristics.
  ARCON 
N=127 (%)
AR 
N=128 (%)
sex   
 male 107 (84) 97 (76)
 female 20 (16) 31 (24)
Median age (range) 61 (42-84) 60 (38-88)
T stage   
 T2 41 (32) 50 (39)
 T3 70 (55) 57 (45)
 T4 16 (13) 21 (16)
N stage   
 N0 82 (65) 82 (64)
 N+ 44 (34) 46 (36)
Unknown 1 (1)  
site   
 glottic 55 (43) 49 (38)
 supraglottic 72 (57) 79 (62)
Differentiation grade   
 well 9 (7) 9 (7)
 moderately 75 (59) 71 (55)
 poor 24 (19) 18 (14)
 unknown 19 (15) 30 (23)
Ki-67-LI   
 high (>10%) 67 (53) 59 (46)
 low (≤10%) 60 (47) 69 (54)
Abbreviations: AR, accelerated radiotherapy; ARCON, accelerated radiotherapy combined with carbogen and 
nicotinamide; Ki-67-LI, labeling index of Ki-67
Fig. 2  Labeling index of Ki-67 is higher in patients with positive lymph nodes (A) or higher T-stage 
(B) at diagnosis.
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Discussion
In this study we showed that larynx cancer patients treated with accelerated radiotherapy 
alone and a high Ki-67-LI have an increased risk of regional and distant metastases 
formation compared to patients with a low Ki-67-LI. In addition, we showed that ARCON 
reduces the incidence of nodal and distant metastatic failures in patients with tumors 
with high proliferative activity.
 Ki-67  expression has been correlated to advanced tumor stage at diagnosis and poor 
histological grading, 7-9 emphasizing the relationship between tumor agressiveness and 
proliferation. Furthermore, Ki-67 has been correlated to clinical outcome in numerous 
studies. The prognostic significance of Ki-67 expression is well established in breast cancer 
and to a lesser extent also in lung cancer and soft tissue tumors.10 Several studies assessed 
the prognostic value of Ki-67 in laryngeal cancer specifically, but mostly in surgically 
treated patients.7,11,12 Some of those have shown a correlation of Ki-67-LI with recurrence 
Fig. 3  Kaplan Meier survival curves for regional control (A), metastasis-free survival (B), local control 
(C) and disease-specific survival (D) in patients treated with accelerated radiotherapy dichotomized 
by the median Ki-67 labeling index.
Fig. 4  Kaplan Meier survival curves show increased regional control and metastasis-free survival 
with ARCON in patients with high Ki-67 expression (B and D). No difference was observed in patients 
with tumors with low Ki-67 expression (A and C).
A B
C D
Low Ki-67 expression High Ki-67 expression
A B
C D
Table 2  Univariate cox regression analysis. 
 
 
Parameter
Local control Regional control Metastasis-free
survival
Disease-specific
survival
AR ARCON AR ARCON AR ARCON AR ARCON
N-stage 0.71* 0.07 0.02 0.05 0.002 0.08 0.01 0.003
Ki-67 0.90 0.63 0.09 0.36 0.004 0.36 0.01 0.13
T-stage 0.63 0.52 0.63 0.40 0.05 0.94 0.03 0.46
Grade 0.67 0.18 0.70 0.23 0.32 0.40 0.45 0.41
Site# 0.14 0.11 0.66 0.08 0.44 0.76 0.68 0.04
Abbreviations: AR, accelerated radiotherapy; ARCON, accelerated radiotherapy combined with carbogen and 
nicotinamide
* p-values are given, bold number indicates significant value # glottic or supraglottic
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High radiation dose and accelerated radiotherapy schedules can overcome this resistance, 
while hypoxic modification can be beneficial for patients who have tumors with a more 
metastasizing phenotype.
Conclusion
High Ki-67 expression is a poor prognostic factor for regional control and metastasis-free 
survival in patients with advanced laryngeal cancer treated with accelerated radiotherapy. 
The addition of hypoxic modification with ARCON reduces regional and distant metastatic 
failures achieving excellent cure rates comparable to that of patients with low proliferative 
tumors.
risk, albeit the exact site of recurrence was not always mentioned.1 One study showed 
prognostic value of high Ki-67 for the occurrence of distant metastasis, consistent with 
findings of the current investigation.13 Results from two randomized trials comparing 
accelerated radiotherapy versus conventional radiotherapy in head and neck cancer 
indicate that tumors with low expression of proliferation markers profit most from 
accelerated radiotherapy regimes with respect to local control.8,14,15  So, low Ki-67 identifies 
patients that could benefit from accelerated radiotherapy to improve local tumor control, 
whereas high Ki-67 is indicative for a metastatic phenotype.
 In the current study, all patients received accelerated radiotherapy, and no prognostic 
value was seen for Ki-67 expression on local control, as can be expected based on the 
previously discussed literature data. However, high Ki-67 expression was correlated with 
worse RC and MFS in patients treated with accelerated radiotherapy alone. So, accelerated 
radiotherapy does not correct for the negative prognostic value of Ki-67 on these 
endpoints, while the addition of hypoxic modification does. How can this be explained?
 There is a mutual relationship between proliferation and hypoxia: highly proliferating 
tumors will rapidly outgrow their vascular supply thus creating hypoxic areas. Furthermore, 
hypoxic conditions can drive a cell towards a more agressive phenotype with invasive and 
migratory potential and more regional and distant metastasis.16  Malignant tumors display 
gradients of hypoxia. Tumor cells at larger distance from the blood vessels under severe 
hypoxia show no or very low proliferative activity.4,17,18 Intermediate levels of hypoxia can 
harbor an aggressive population of tumor cells, that have a larger capability of proliferation 
and formation of metastasis (regional or distant). This intermediate hypoxic cell population 
may be more relevant for the effect of ARCON than the severely hypoxic cells. This is why 
we analyzed colocalization between Ki-67 and CAIX as a marker for intermediate hypoxia. 
Although we did observe an association between colocalization parameters and 
metastases formation and effect of ARCON, the predictive power was not better than that 
of Ki-67 as a single marker. This could be due to the fact that CAIX  expression is not only 
related to hypoxia. In the current material we observed a diffuse (hypoxia-unrelated) 
expression pattern in 56% of the laryngeal tumors (data not shown).
 Most studies report locoregional control as an outcome measure for head and neck 
cancer. However, differentiation between local and regional control might be more 
appropriate as local failure is likely caused by different mechanisms than regional and 
distant failures. For a tumor to spread through lymph and blood vessels, cells must have 
migratory capacity by transformations like epithelial mesenchymal transition. Hypoxia can 
drive tumor cells towards this migratory phenotype and at the same time protect these 
cells from radiation-induced injury. Hence, a beneficial effect of hypoxia modifying 
treatment can be expected through sensitization of this critical cell population. A local 
recurrence can be caused by radioresistent cells with a large capacity for repair and 
repopulation, in which hypoxia might play a minor role. Indeed, it has been suggested 
that well differentiated tumors have this ability more than poorly differentiated tumors.19,20 
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Discussion
This thesis investigated the addition of carbogen breathing and nicotinamide to accelerated 
radiotherapy (ARCON) in patients with advanced laryngeal cancer and the possibilities to 
select the patients that will benefit most from this approach.
Hypoxic modification and patient selection
The adverse prognostic impact of hypoxia in head and neck cancer prompted several 
approaches to counteract this resistance mechanism. As multiple methods are available 
to measure hypoxia in tumors, these hypoxia-modifying treatments are often combined 
with the assessment of the hypoxic state of the tumor to select the patients who will 
benefit from the hypoxia-modifying treatment.
 Chapter 2 describes the results of a randomized trial comparing accelerated radio- 
therapy alone with ARCON. There was no significant difference in the primary endpoint, 
local control rate, while the 2- and 5-year regional control rates were significantly better 
with ARCON. Important to note on this point is the fact that in the patients treated with 
ARCON the total dose on the larynx was 64 Gy instead of 68 Gy to reduce the risk of 
laryngeal necrosis. In the patients with hypoxic tumors, based on pimonidazole staining, 
ARCON treatment resulted in a regional control rate of 100% compared to 55% with 
accelerated radiotherapy alone, whereas no difference was seen in the patient group with 
non-hypoxic tumors, emphasizing the importance of patient selection. 
 Several other strategies of patient selection for hypoxia-modifying treatments have 
been attempted over the last years. 
 In a side study of the DAHANCA 5 randomized trial, studying the addition of nimorazole 
to radiotherapy in head and neck cancer, the investigators showed that the plasma level 
of osteopontin, as an indirect measure for tumour hypoxia, can be indicative for the 
respons to hypoxic sensitization.1 Only patients with high plasma levels of osteopontin 
profited from the addition of nimorazole. The HPV-status of the patient is a possible 
selection tool as well, with a significant gain of oxygen modification in HPV-negative 
patients, but not in HPV-positive patients.2 A stronger prediction model making use of a 
hypoxia gene expression classifier has been published recently. Only HPV-negative 
patients with hypoxic tumors based on the 15-gene hypoxia classifier profited from the 
addition of nimorazole, resulting in a significantly higher locoregional control and disease-
specific survival.3,4 Attempts have been made to predict the response to tirapazamine 
with osteopontin, hepatocyte growth factor and interleukin-8 with negative results.5,6 
Rischin et al. demonstrated the feasibility of selecting patients for tirapazamine treatment 
based on (18F)-fluoromisonidazole-PET scanning,7 but no randomized trial has been 
conducted with this concept. The phase III trial with tirapazamine in an unselected patient 
population showed no benefit of hypoxic modification, emphasizing the importance of 
patient selection in large randomized trials.
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 Even though the presence of a tumor cell population staining positive for pimonidazole 
points at tumor cell adaptation enabling survival under hypoxic conditions, it is important 
to realize that pimonidazole is a chemical assessment of hypoxia, and contains no 
information on the biological response of the tumor cell to the hypoxic conditions. 
Endogenous hypoxia-related markers
Above mentioned drawbacks do not apply to endogenous markers; paraffin embedded 
biopsies taken for routine diagnostic purposes can be used to stain several markers. 
Endogenous hypoxia-related markers, alone or in combination, could be candidates to 
predict the response to ARCON treatment and can further clarify the cellular response to 
hypoxia. In Chapter 3, a method for analysis of colocalization of markers in different 
subcellular compartments is described as this can be more informative on the function 
of a protein than analysis of a single marker. The combination of CAIX and Ki-67 was 
investigated, as a previous study showed prognostic value of a subpopulation of 
proliferating cells under hypoxic conditions.12 The method can be applied with numerous 
other markers. An additional finding was the good correlation of the CAIX fraction and 
Ki-67 labeling index between multiple biopsies of a same tumor. Often, it is questioned 
whether the analysis of a single tissue section is representative due to the intratumoral 
variation. The results from this chapter indicate that a single section provides a good 
approximation, at least for the markers investigated.
CAIX
Against expectations, the combination of CAIX and Ki-67 showed no additional value as a 
prognostic or predictive factor compared to each of the markers alone (Chapter 6). This 
could be due to the fact that CAIX is not only a hypoxia-related marker as hypothesized in 
Chapter 5. In this chapter the relevance of the pattern of CAIX is described. In some tumors 
CAIX shows a typical perinecrotic pattern, that seems hypoxia-related and in other tumors 
a more diffuse pattern is observed, often in well-differentiated keratinizing areas, that 
seems not related to hypoxia. The perinecrotic pattern is the one most described in the 
literature13 and indicates worse patient outcome with higher CAIX expression. The diffuse 
pattern has been described before in renal cell carcinoma, with a reversed prognostic 
value of CAIX.14 Considered in that light, the reversed prognostic and predictive value of 
CAIX in the ARCON randomised trial (Chapter 5, worse regional control and metastasis-
free survival in patients with a low CAIX expression, correction by ARCON) is less surprising 
as 145 of the 187 CAIX-positive tumors exhibited a diffuse CAIX staining pattern. The 
different patterns could be the result of different mechanisms of upregulation of CAIX. 
The best known trigger for CAIX upregulation is through HIF-1α stabilization by hypoxia, 
which can be expected to play an important role in the perinecrotic expression pattern. 
Pathways or factors other than hypoxia can be involved in HIF-1α stabilization and CAIX 
upregulation in normoxic circumstances, like PI3-K pathway activation,15 acidosis16,17 and 
 To conclude, hypoxia-modifying therapies are effective in head and neck cancer. A 
meta-analysis of randomized trials applying oxygen-enhanced radiotherapy showed 
increased locoregional control, disease-specific survival and overall survival.8 However, it is 
indispensable to select the patients that will profit most from hypoxia-modifying 
treatments using direct or surrogate markers of tumor hypoxia.
Radiotherapy combined with chemotherapy and targeted therapies
Nowadays, the standard treament for advanced head and neck cancer, including laryngeal 
cancer, is chemoradiation. It is important to note that no biological markers are available 
tot predict the respons to chemoradiation.9 The selection of patients is based on clinical 
characteristics like tumor volume, nodal stage and performance status.  HPV status is currently 
under investigation as a possible selection method for radiotherapy or combined treatment. 
 A plethora of targeted therapies has been developed and many are tested in clinical 
studies. In head and neck cancer the best known is cetuximab, an antibody directed 
against the epidermal growth factor receptor. In a randomized phase III trial in patients 
with advanced head and neck cancer 5-year-survival was higher with combined treatment 
(46% vs 36% with radiotherapy alone).10 Unfortunately, increased skin toxicity is reported 
with cetuximab11 and no validated selection tool is available at the moment. 
 Many targeted therapies fail in the majority of patients due to tumor heterogeneity 
and evasion mechanisms. The strength of ARCON is that it specifically tackles hypoxia, a 
general resistance mechanism.
Predictive markers for ARCON
In this thesis several markers have been evaluated on their relation with hypoxia and their 
applicability as predictive markers. 
Pimonidazole
Although the hypoxic fraction as assessed by the exogenous marker pimonidazole 
staining as described in Chapter 2 can predict the response to ARCON, it has some 
practical drawbacks for implementation in clinical practice. Pimonidazole has to be 
administered intravenously before biopsy taking, at a time that the diagnosis is not 
confirmed yet. Furthermore, with the quantitative method we described additional fresh 
frozen biopsies are needed. The method of analysis is highly suited for a large series of 
biopsies, but less suitable for assessment of the hypoxic state of an individual biopsy, due 
tot day-to-day variation in staining and thresholding. Recently, an oral formulation of 
pimonidazole has become available, that can circumvent some of the drawbacks. 
Pimonidazole staining on paraffin biopsies should be validated and this could be 
implemented in daily practice.
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Site of recurrence
Most studies report locoregional control as an outcome measure for head and neck 
cancer. However, differentiation between local and regional control might be more 
appropriate as local failure is likely caused by different mechanisms than regional and 
distant failures. A local recurrence can be caused by radioresistent cells with a large 
capacity for repair and repopulation. It has been suggested that well differentiated tumors 
have this ability more than poorly differentiated tumors.22,24 High radiation dose and 
accelerated radiotherapy schedules can overcome this resistance. In hypoxic tumors 
radioresistent cells in hypoxic areas can play an important role in local recurrence as well 
and in patients with these tumors hypoxia modifying treatment can be beneficial. 
 For a tumor to spread through lymph and blood vessels, cells must have migratory 
capacity by transformations like epithelial mesenchymal transition.31 Hypoxia can drive 
tumor cells towards this migratory phenotype32 and at the same time protect these cells 
from radiation-induced injury, leading to regional and distant failure. Hence, a beneficial 
effect of hypoxia modifying treatment on regional and distant control can be expected 
through sensitization of this critical cell population in patients who have hypoxic tumors 
with a more metastasizing phenotype.
Other head and neck tumor sites 
This thesis comprises only a distinct subgroup of all head and neck cancers i.e. laryngeal 
carcinoma. Etiological factors differ between the specific head and neck subsites.33,34 
Previous investigations showed that laryngeal carcinomas harbour a restricted spectrum 
of p53 mutations35 and are often better differentiated than other head and neck subsites. 
Such differences can have major impact on the expression of tumor markers and the 
response to therapy. Most studies include patients with different subsites of head and 
neck cancer. However, the discovery of HPV as an etiological factor in oropharyngeal 
cancer emphasizes the differences in tumor biology and the heterogeneity of this type of 
cancer.
Future considerations
As more treatment options become available for patients with laryngeal cancer and more 
knowledge is gained about the variation in tumor biology, selection of patients for the 
most beneficial treatment is indispensable.
 It seems that the typical well-differentiated tumor with low Ki-67 expression and 
diffuse CAIX staining already profits from accelerated radiotherapy with respect to local 
control and has a low chance of metastasizing. The typical poorly differentiated tumor 
with high ki-67 expression and low CAIX staining profits from hypoxic modification with 
ARCON with respect to RC and MFS. Perinecrotic CAIX staining is a poor prognostic factor, 
especially for the development of distant metastasis, perhaps these patients could profit 
from chemoradiation or adjuvant chemotherapy.
genetic alterations, e.g. VHL or p53 mutations. This explains the often weak correlation 
with clinically relevant hypoxia.18-20 This diffuse pattern could be more  for laryngeal 
carcinoma, as it has not been described in studies including other head and neck sites.
 So, CAIX can predict the respons to ARCON therapy in advanced laryngeal cancer, 
although in a different way than expected beforehand. Furthermore the CAIX staining 
pattern seems indicative for the tumor phenotype and predicts outcome. 
Proliferation and the response to ARCON
Accelerated radiotherapy improves local control compared to conventionally fractionated 
radiotherapy.21,22 An important cause of treatment failure is accelerated repopulation 
occuring during the course of radiation treatment.23 To overcome this resistance, treatment 
time is shortened from seven to five or six weeks. 
 Although repopulation is related to proliferation, the ability of the tumor to repopulate 
effectively will not solely depend on the proliferation status of the tumor before treatment, 
but also on the ability of the tumor to react to radiotherapy-induced cell kill. It has been 
suggested that the ability to accelerate repopulation is a characteristic of well to 
moderately differentiated tumors and may be lost by dedifferentiation.24
 High proliferation status has been often described as associated with advanced 
tumor status and is an adverse prognostic factor in many studies.25 Ki-67, an endogenous 
proliferation marker, is widely used, mostly in surgical series. but several studies have 
investigated the relation between proliferation status of the tumor and response to 
radiation as well,26,27 and conclude that tumors with low proliferative activity benefit most 
from accelerated treatment. In the standard arm of the ARCON trial (accelerated 
radiotherapy alone) patients with low Ki-67 expression indeed did have an excellent local 
and regional control (Chapter 6). However, in patients with high Ki-67 expression an 
increased rate of regional and distant metastasis was observed with AR, while the addition 
of hypoxic modification corrects for this negative prognostic factor. The explanation for 
this phenomenon could be found in the mutual relationship between hypoxia and 
proliferation: highly proliferating tumors will rapidly outgrow their vascular supply thus 
creating hypoxic areas. Furthermore, hypoxic conditions can drive a cell towards a more 
agressive phenotype with invasive and migratory potential and more regional and distant 
metastasis.28 Malignant tumors display a gradient of hypoxia. Tumor cells at larger distance 
from the blood vessels under severe hypoxia show no or very low proliferative activity.12,29,30 
Intermediate levels of hypoxia can harbor an aggressive population of tumor cells, that 
have a larger capability of proliferation and formation of metastasis (regional or distant). 
This intermediate hypoxic cell population may be more relevant for the effect of ARCON 
than the severely hypoxic cells.
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 The last question is, if we really need a hypoxic marker if more agressive tumors in 
general (although often characterized by hypoxia) profit from ARCON. A simple predictive 
assay based on TNM stage, differentiation, proliferation and hemoglobin levels (data not 
published yet) could be an excellent tool to select patients for this hypoxia-modifying 
treatment with low toxicity. However, until now, pimonidazole is the strongest predictor 
for the response to ARCON.
Although this thesis investigates ARCON in laryngeal cancer specifically, this treatment has 
the potential to improve the outcome of all tumors with an hypoxic phenotype, 
irrespective of tumor site, e.g. other head and neck sites, gynaecological and bladder 
tumors. Hypoxia is an adverse prognostic factor in all head and neck cancer subsites and 
hypoxic modification with nimorazole has shown to improve outcome of tumors at 
different subsites. Furthermore, the phase II ARCON trial showed an excellent outcome in 
advanced oropharyngeal carcinomas besides carcinomas of the larynx. 
 In bladder cancer addition of carbogen breathing and nicotinamide to radiotherapy 
has already shown improved local control and overall survival,36 making it an organ-pre-
serving alternative to radical cystectomy. In gynaecological cancer most cervical tumors 
are squamous cell carcinomas, the most prevalent histology in head and neck cancer as 
well. Furthermore, analogous to head and neck tumors, in cervical carcinomas hypoxia is 
a major resistance mechanism that impairs outcome and a beneficial effect of hypoxic 
modification can be expected on theoretical grounds.
Concluding remarks
The addition of carbogen breathing and nicotinamide enhances the effect of accelerated 
radiotherapy and improves the outcome in a selection of patients with advanced laryngeal 
cancer. The exogenous marker pimonidazole and several endogenous markers can be 
applied to predict the response. These markers, combined with clinical characteristics, can 
select patients for ARCON. Oncological therapies are changing from the ‘one treatment 
fits all’ concept to individualized medicine. It is already applied in several types of cancer 
and this is only the beginning of a new era in cancer treatment.
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Summary
Hypoxia is an important cause of treatment resistance to radiotherapy in head and neck 
cancer. In this thesis the addition of hypoxic modification to radiotherapy is investigated 
as a treatment for advanced laryngeal carcinoma. In addition, prognostic and predictive 
exogenous and endogenous markers are evaluated.
In Chapter 1 an overview is given of the role and pathophysiology of hypoxia, methods 
of quantification and hypoxia-targeting therapies in head and neck cancer with emphasis 
on laryngeal cancer. Hypoxia is a negative prognostic factor in head and neck cancer 
related to tumor aggressiveness and treatment resistance, for the effect of radiotherapy 
on tumor cells is strongly dependent on the presence of oxygen. Hypoxia is caused by an 
imbalance between the supply and consumption of oxygen due to rapid growth of a 
malignant tumor and morphological and functional deformed blood vessels. Tumor cells 
at a large diffusion distance from a blood vessel will endure chronic hypoxic circumstances, 
however, due to a temporary disruption of the blood flow, transient hypoxic conditions 
can exist close to a blood vessel. The result of these mechanisms is a gradual scale of 
hypoxia within a tumor. The relation of hypoxia with tumor metabolism and proliferation 
is discussed.
 Several methods of measuring hypoxia are available; invasive techniques, exogenous 
markers and endogenous markers. The prognostic value of several hypoxia- and 
metabolism-related endogenous markers is reviewed. Finally, several hypoxia-targeting 
treatment approaches are described, with emphasis on ARCON (Accelerated Radiotherapy 
plus Carbogen and Nicotinamide).
 Chapter 2 describes the results from a randomized trial comparing Accelerated 
Radiotherapy (AR) with ARCON in laryngeal cancer.
 Patients with cT2-4 squamous cell laryngeal cancer were randomized to AR (68 Gy 
within 36-38 days) or ARCON (AR plus carbogen inhalation and nicotinamide). To limit the 
risk of laryngeal necrosis, ARCON patients received 64 Gy on the laryngeal cartilage. The 
primary endpoint was local control. Secondary endpoints were regional control, larynx 
preservation, toxicity, disease-free survival and overall survival. In a translational side study 
the hypoxia marker pimonidazole was used to assess the oxygenation status in tumor 
biopsies.  
 From 04-2001 to 02-2008, 345 patients were accrued. After a median follow-up of 44 
months, local tumor control rate at 5 years was 78% for AR versus 79% for ARCON (p=0.80) 
with corresponding larynx preservation rates of 84% and 87% (p=0.48). The 5-year regional 
control was significantly better with ARCON (93%) compared to AR (86%, p=0.04). The 
improvement in regional control was specifically observed in patients with hypoxic 
tumors and not in patients with well-oxygenated tumors (100% versus 55% respectively, 
p=0.01). AR and ARCON produced equal levels of toxicity.
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 In Chapter 5 the prognostic and predictive value of the hypoxia-associated protein 
CAIX in the ARCON phase III trial is investigated. 261 paraffin embedded tumor biopsies 
and 79 fresh frozen biopsies from patients entered in the trial were immunohistochemically 
stained for CAIX. CAIX-fraction and CAIX expression pattern were related to tumor control 
and patient survival. Low CAIX-fraction was prognostic for worse regional control and 
overall survival in patients treated with AR. Patients with a low CAIX-fraction treated with 
ARCON had better regional control and metastasis-free survival compared to AR (RC 97% 
vs 71%, p<0.01 and MFS 92% vs 69%, p=0.06). Besides the CAIX-fraction, the pattern of 
CAIX expression was investigated as well. Patients with a perinecrotic CAIX staining 
pattern had a significantly worse local control, metastasis-free and overall survival 
compared to patients with a diffuse pattern (65% vs 84%, p=0.01, 70% vs 96%, p<0.01 and 
42% vs 71%, p<0.01 respectively), and this could not be improved with ARCON. After 
multivariate analysis CAIX pattern and N-stage emerged as significant predictors for 
metastasis-free survival and overall survival. In conclusion, ARCON improves regional 
control and metastasis-free survival only in patients with low CAIX expression. The 
different patterns of CAIX expression suggest different mechanisms of upregulation of this 
glycoprotein and have important prognostic value.
 In Chapter 6 the prognostic and predictive value of Ki-67 was studied, as well as the 
colocalization with CAIX, applying the method described in Chapter 3. Tumor biopsies 
from 255 patients were immunohistochemically stained for Ki-67 and the hypoxia-related 
marker CAIX. Labeling index of Ki-67 (Ki-67-LI) and the colocalization with CAIX was related 
to tumor control and patient survival. On average, tumors from node positive patients had 
a higher Ki-67-LI compared to node negative patients (median 14% vs 8% p < 0.01). In the 
cohort treated with AR alone high Ki-67-LI (>10%) was associated with increased regional 
and distant metastases formation.  This was not observed in the patients treated with 
ARCON. Regional- and distant metastases-free survival were 79% vs 96%, p < 0.01 and 71% 
vs 88% p = 0.05, for AR and ARCON, respectively. Local control and disease-specific survival 
were not significantly different between the treatment arms (78% vs 80%, p = 0.91 and 
70% vs 76%, p = 0.53). Patients with low Ki-67 expressing tumors had an excellent outcome 
with accelerated radiotherapy and this could not be further improved with ARCON. 
Colocalization of Ki-67 with CAIX provided no additional prognostic information. It was 
concluded that patients with larynx carcinomas with high proliferative activity are at 
increased risk of regional and distant metastases formation. This risk can be reduced by 
treatment with ARCON.
 It was concluded that, despite lack of benefit in local tumor control for advanced 
laryngeal cancers, a significant gain in regional control rate, with equal levels of toxicity, 
was observed in favor of ARCON. The poor regional control of patients with hypoxic 
tumors is specifically countered by ARCON treatment.
 Chapter 3 introduces an automated analysis of immunohistochemically stained 
tissue sections to assess the colocalization of tumor-specific prognostic markers. Here, the 
automated quantitative analysis is used to assess the colocalization of carbonic anhydrase 
IX (CAIX), a membrane-bound hypoxic marker and Ki-67, a nuclear proliferation marker. 
Tissue sections of 104 biopsies from 89 patients were stained for CAIX and Ki-67 with 
diaminobenzidine and haematoxylin counterstain. Image scans of whole tumor sections 
were recorded and image maps were created with parametric mapping to quantify the 
markers and assess the colocalization. The fraction of CAIX showed a range of 0–93%. The 
interobserver correlation and the correlation between manual scores and automated 
analysis were both very strong (rs=0.96, p <0.0001, and rs=0.97, p <0.0001). The labelling 
index of Ki-67 exhibited a range of 0–42% with less strong but still satisfactory interobserver 
and manual to automated analysis correlations (rs=0.90, p <0.0001, and rs=0.71, p <0.0008). 
The relative tumor area positive for both markers varied from 0 – 76%. From these results, 
it was concluded that parametric mapping of immunohistochemically stained tumor 
sections is a reliable method to quantitatively analyze membrane-bound proteins and 
assess the colocalization of various tumor markers in different subcellular compartments.
 The cellular response of malignant tumors to hypoxia is diverse. Several important 
endogenous metabolic markers are upregulated under hypoxic conditions. In Chapter 4 
we examined the staining patterns and co-expression of HIF-1α, CAIX, LDH-5, GLUT-1, 
MCT1 and MCT4 with the exogenous hypoxic cell marker pimonidazole and the association 
of marker expression with clinicopathological characteristics. Biopsies of 20 advanced 
head and neck carcinomas were immunohistochemically stained and analyzed. All 
patients were given the hypoxia marker pimonidazole intravenously 2 h prior to biopsy 
taking. The tumor area positive for each marker, the colocalization of the different markers 
and the distribution of the markers in relation to the blood vessels were assessed by 
semiautomatic quantitative analysis. MCT1 staining was present in hypoxic (pimonidazole 
stained) as well as non-hypoxic areas in almost equal amounts. MCT1 expression showed 
a significant overall correlation (r=0.75, p<0.001) and strong spatial relationship with CAIX. 
LDH-5 showed the strongest correlation with pimonidazole (r=0.66, p=0.002). MCT4 and 
GLUT-1 demonstrated a typical diffusion-limited hypoxic pattern and showed a high 
degree of colocalization. Both MCT4 and CAIX showed a higher expression in the primary 
tumor in node positive patients (p=0.09 both). Therefore, colocalization and staining 
patterns of metabolic and hypoxia-related proteins provides valuable additional 
information over single protein analyses and can improve the understanding of their 
functions and environmental influences. 
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Samenvatting
Hypoxie is een belangrijke oorzaak van resistentie voor radiotherapie in hoofd-hals kanker. 
In dit proefschrift wordt de toevoeging van hypoxie-modificatie aan radiotherapie onder- 
zocht als behandeling voor gevorderde stadia van het larynxcarcinoom. Daarbij wordt 
gekeken naar prognostische en predictive markers die de juiste patienten voor deze 
behandeling kunnen selecteren. Onderstaande is een verkorte samenvatting van 
hoofdstuk 1.
Larynxcarcinoom en radiotherapie
De incidentie van het larynxcarcinoom is ongeveer 700 nieuwe patienten per jaar. 
Het treft meer mannen dan vrouwen in de verhouding 7:1. Echter, de incidentie onder 
vrouwen neemt toe, waarschijnlijk ten gevolge van veranderingen in rookgedrag, de 
belangrijkste etiologische factor. Andere factoren die bijdragen aan het ontstaan van het 
larynxcarcinoom zijn alcoholgebruik en in mindere mate beroepsblootstelling en humaan 
papilloma virus (HPV). In de meeste gevallen betreft het een plaveiselcelcarcinoom, in 2/3 
van de gevallen supraglottisch gelokaliseerd. De behandeling voor vroege stadia bestaat 
uit laserchirurgie of radiotherapie met zeer goede lange termijn resultaten. De behandeling 
van vergevorderde stadia bestaat uit radiotherapie, al of niet gecombineerd met 
chemotherapie, maar een aanzienlijk deel van de patienten ontwikkelt een locoregionaal 
recidief of metastasen op afstand. Hypoxie (gebrek aan zuurstof) is een belangrijk 
resistentie mechanisme wat het slagen van de behandeling in de weg kan staan. Het 
effect van radiotherapie is namelijk sterk afhankelijk van de aan- of afwezigheid van 
zuurstof. 
Hypoxie in maligne tumoren
In bijna alle maligniteiten speelt hypoxie een belangrijke rol. Het is een negatief 
prognostische factor, doordat hypoxische tumoren resistenter zijn voor chemo- en 
radiotherapie en zich een meer agressief tumor phenotype kan ontwikkelen in hypoxische 
omstandigheden.
 Hypoxie ontstaat door een disbalans tussen de aanvoer en het verbruik van zuurstof. 
In maligne tumoren vormt zich door de snelle groei vaak een chaotische microvasculatuur 
met slecht functionerende bloedvaten, waardoor de zuurstof toevoer verstoord is. 
Tumorcellen op grote diffusieafstand van de bloedvaten hebben een chronisch tekort aan 
zuurstof, maar ook dichtbij de vaten, door een tijdelijk verstoring van de bloedstroom, kan 
tijdelijk hypoxie voorkomen. Het gevolg is een gradient van hypoxie  in het tumorweefsel. 
Het tumormetabolisme past zich aan aan deze hypoxische omstandigheden door een 
verhoogde mate van anaerobe glycolyse in plaats van oxidatieve fosforylering. Echter, 
veel maligne tumoren hebben ook in de aanwezigheid van voldoende zuurstof al een 
verhoogde mate van glycolyse (Warburg effect), waardoor een verhoogd verbruik van 
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Samenvatting van de navolgende hoofdstukken
Hoofdstuk 2 beschrijft de resultaten van een gerandomiseerde studie die geaccelereerde 
bestraling (AR) vergelijkt met ARCON in 345 patienten met een cT2-4 larynxcarcinoom. 
Het primare eindpunt was locale controle, secundaire eindpunten waren regionale 
controle, larynxpreservatie, toxiciteit, ziekte-vrije overleving en totale overleving. Voor het 
translationele gedeelte van de studie werd pimonidazole toegediend aan een deel van 
de patienten om de oxygenatie status van de tumor vast te stellen. Locale controle na 5 
jaar was 78% voor AR versus 79% voor ARCON (p = 0.80). De 5-jaars regionale controle was 
beter met ARCON (93%) vergeleken met AR (86%, p=0.04). Een grotere winst in regionale 
controle werd behaald in patienten met hypoxische tumoren (100% met ARCON versus 
55% met AR, p=0.01). De toxiciteit was gelijk in beide armen. Geconcludeerd werd dat, 
ondanks het gebrek aan verbeterde locale controle, met ARCON een significante 
verbetering van regionale controle werd behaald in gevorderde stadia larynxcarcinoom, 
met name in patienten met hypoxische tumoren.
 Om in deze gerandomiseerde studie de prognostische en predictieve waarde van 
verschillende endogene hypoxie-gerelateerde markers te kunnen onderzoeken wordt in 
hoofdstuk 3 een automatische analyse van immunohistochemisch gekleurde weefsel 
coupes geїntroduceerd, welke geschikt is om de colocalisatie van tumor-specifieke markers 
te bepalen.  In deze studie werd in 104 biopten van 89 patienten de colocalisatie van CAIX 
en Ki-67 bepaald. Hele coupes werden gescand en met parametric mapping werden 
numerieke beeldkaarten gegenereerd om de markers te kwantificeren en de colocalisatie te 
berekenen. De correlatie tussen de handmatige score en automatische analyse was hoog 
voor CAIX (rs=0.97, p <0.0001) en Ki-67 (rs=0.71, p <0.0008). Het relatieve tumoroppervlak 
positief voor beide markers varieerde van 0 - 76%. Uit deze resultaten werd geconcludeerd 
dat parametric mapping van immunohistochemisch gekleurde tumor coupes een 
betrouwbare methode is om kwantitatief membraangebonden eiwitten te analyseren en de 
colocalisatie van tumor markers in verschillende subcellulaire compartimenten vast te stellen.
 Een andere groep van potentiele predictieve markers, die veelvuldig tot expressie 
komen in  maligne tumoren en met name in hypoxische omstandigheden, zijn de meta-
bolisme-gerelateerde endogene markers. In hoofdstuk 4 werd het expressie patroon en 
de co-expressie van HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 en MCT4 met pimonidazole 
onderzocht, en de associatie van deze markers met tumor- en patiёntkarakteristieken in 
20 vriesbiopten van gevorderde stadia hoofd-hals tumoren.
 MCT1 expressie was in gelijke hoeveelheden aanwezig in zowel hypoxische als 
 niet-hypoxische gebieden en toonde een sterke correlatie in plaats en hoeveelheid met 
CAIX. LDH liet de sterkste correlatie met pimonidazole zien (r=0.66, p=0.002). Een typisch 
diffusie-gelimiteerd hypoxisch patroon werd gezien bij MCT4 en GLUT-1, welke een hoge 
mate van colocalisatie toonden. De expressie van MCT4 en CAIX was hoger in patiёnten 
met lymfekliermetastasen bij diagnose (p=0.09 beide).
glucose en vorming van lactaat. Een ander kenmerk van maligne tumoren is de hoge 
proliferatiesnelheid. Het is gecorreleerd met agressieve tumorkenmerken en leidt tot een 
slechtere uitkomst voor de patient. Een veelgebruikte endogene marker om proliferatie te 
meten is Ki-67. Een subgroep van tumorcellen die ondanks de hypoxie wel in staat zijn om 
te prolifereren,  zou de oorzaak kunnen zijn van persisterende of recidiverende ziekte.
Meten van hypoxie
Er zijn verschillende methoden om hypoxie in het tumorweefsel te meten. De focus ligt 
tegenwoordig op exogene markers, zoals pimonidazole, en een hele range aan endogene 
tumormarkers. Pimonidazole wordt intraveneus toegediend en bindt aan thiol-bevatten-
de eiwitten in levende hypoxische cellen. Het heeft prognostische waarde in hoofd-hals 
tumoren, waarbij patiёnten met een hoge hypoxische fractie een slechtere locoregionale 
controle en ziekte-vrije overleving hebben. Het voordeel van de endogene markers is dat 
ze bepaald kunnen worden op gearchiveerde biopten, zonder voorafgaand infuus, maar 
er is nog geen marker bekend die herhaaldelijk, robuuste resultaten geeft met betrekking 
tot prognostische waarde. Een belangrijke potentiele kandidaat is HIF-1 (hypoxia-induci-
ble factor-1), welke de spil is in de cellulaire respons op hypoxie en onder andere proliferatie, 
apoptose, angiogenese, pH balans en metabolisme reguleert. Het induceert de expressie 
van carbonic anhydrase IX (CAIX), betrokken bij de pH regulatie, glucose transporters 
(GLUT’s), monocarboxylaat transporters (MCT’s) en lactaat dehydrogenase (LDH), allen 
betrokken bij het celmetabolisme en de glycolyse.
Hypoxie-modificerende behandelingen
Verschillende behandelstrategieёn zijn toegepast specifiek gericht tegen hypoxie in 
tumoren: verhogen van de beschikbaarheid van zuurstof, toxines specifiek gericht op 
hypoxische cellen en het verminderen van de radioresistentie. ARCON combineert versnelde 
bestraling met ademen van carbogeen (98% zuurstof) en de toediening van nicotinamide 
om een zo hoog mogelijke zuurstofspanning in de tumor te verkrijgen. Het heeft in een 
fase II studie een zeer goed resultaat laten zien in gevorderde stadia hoofd-hals tumoren.
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 Geconcludeerd werd dat colocalisatie en expressie patronen van metabole en hypo-
xie-gerelateerde eiwitten waardevolle informatie toevoegt aan analyse van enkele 
eiwitten. Dit kan het begrip en de kennis van de functie van deze eiwitten en de reactie 
van de tumorcel op de omgeving vergroten.
 In hoofdstuk 5 werd apart de prognostische en predictieve waarde van CAIX in de 
ARCON fase III studie onderzocht aan de hand van 261 paraffine biopten en 79 vriesbiopten. 
Patiёnten met een lage CAIX-fractie behandeld met AR hadden een slechtere regionale 
controle en totale overleving dan patiёnten met een hoge CAIX-fractie. Met ARCON werd, 
vergeleken met AR, een hogere regionale controle (97% vs 71%, p<0.01) en metastase-
vrije overleving (92% vs 69%, p=0.06) gezien in patiёnten met een lage CAIX-fractie. Het 
patroon van CAIX expressie (perinecrotisch, diffuus of geen patroon) was een belangrijke 
prognostische factor, waarbij een slechtere locale controle, metastase-vrije overleving en 
totale overleving werd gezien bij patiёnten met een perinecrotisch expressie patroon. Dit 
kon niet verbeterd worden met ARCON. CAIX patroon en N-stadium verschenen als enige 
significante voospellers voor metastase-vrije overleving en totale overleving in multivariate 
analyse. Geconcludeerd werd dat ARCON een betere regionale controle en metastase-vrij 
overleving geeft in patiёnten met een lage CAIX expressie. Het patroon van CAIX expressie 
suggereert een verschillend mechanisme van opregulatie en is van prognostische 
betekenis.
 In hoofdstuk 6 werd de prognostische en predictieve waarde van Ki-67 en de 
colocalisatie van Ki-67 met CAIX onderzocht met behulp van de methode uit hoofdstuk 3 
in tumor biopten van 255 patiёnten. Patiёnten met lymfekliermetastasen bij diagnose 
hadden een hogere Ki-67 labeling index (Ki-67-LI) dan patiёnten zonder aangedane 
lymfeklieren (14% vs 8% p<0.01). Ki-67-LI was een slechte prognostische factor in patiёnten 
behandeld met AR alleen. In patiёnten met een hoge Ki-67-LI waren de regionale controle 
en ziekte-vrije overleving hoger met ARCON vergeleken met AR (96% vs 79%, p<0.01 and 
88% vs 71% p=0.05, respectievelijk). Locale controle en ziekte-specifieke overleving 
verschilden niet significant. Patiёnten met een lage Ki-67-LI hadden een zeer goede 
uitkomst met AR, dit kon niet verder worden verbeterd met ARCON. Colocalisatie van 
Ki-67 met CAIX gaf geen additionele prognostische informatie. Het blijkt dus dat patiёnten 
met een larynxcarcinoom met een hoge mate van proliferatie meer kans hebben op klier- 
en afstandsmetastasen. Dit kan worden verminderd door behandeling met ARCON.
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Dankwoord
Mijn proefschrift ligt bij de manuscriptcommissie, zelf ben ik net terug van vakantie, dit 
lijkt een prima moment om aan het dankwoord te beginnen. Zonder de bijdragen van 
collega’s, familie, vrienden en patiënten was dit proefschrift er niet gekomen, dus als 
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persoonlijk bedanken.
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Prof. Kaanders, beste Hans, vanaf het begin heb je alle vertrouwen in mijn promotietraject 
gehad, waardoor ik zelf ook altijd het geloof hield dat het ooit af zou komen, ook al leek 
het einde soms ver weg. Verder wil ik je bedanken voor je immer grondige en kritische 
becommentarisering van al mijn teksten, waardoor elke versie nog beter werd dan de 
vorige. 
Dr. Bussink, beste Jan, het was erg fijn om met jou samen te werken door je enthousiasme 
voor het onderzoek en je altijd aanwezige bereidheid tot laagdrempelig overleg. 
Promoveren leek ineens niet meer zo moeilijk: “nietje erdoor, en klaar!”
Prof. Van der Kogel, beste Bert, het was een eer om met je samen te mogen werken. Ik heb 
zeer veel respect voor wat je bereikt hebt en de manier waarop je in je werk staat. Ik 
waardeer je enthousiasme om je kennis over te dragen aan de volgende  generatie.
 
Een langdurig en soms frustrerend project zoals een promotie is bijna onmogelijk zonder 
fijne collega’s die je ondersteunen met opbeurende woorden, grappen, koffie en 
gezelligheid. Dus hierbij wil ik alle mede-AIOS en -onderzoekers bedanken, die hiervoor 
ruimschoots hebben gezorgd de afgelopen 6 jaar. Hanneke, jij als eeuwige kamergenoot 
en fijne collega bent voor mij dan ook een vanzelfsprekende keuze als paranimf, bedankt 
dat je deze (zware) taak op je wilt nemen.
Wenny, Jasper en Hans, bedankt, jullie zorgden naast de praktische ondersteunende 
werkzaamheden voor spreekwoordelijk licht in het duistere microscopenlab. Alle andere 
medewerkers van de afdeling radiotherapie wil ik bedanken voor hun begrip, interesse en 
gezellige tijd, zonder jullie was dit ook niet mogelijk geweest.
Wie niet mogen ontbreken in dit dankwoord zijn de patiënten die belangeloos hebben 
meegewerkt aan deze studie in het kader van wetenschappelijk onderzoek, bedankt, 
zonder jullie was er geen proefschrift geweest. Tevens was het klinische werk met 
patiëntencontact een welkome afwisseling van het  wetenschappelijke werk en gaf het 
me elke keer weer de moed en zin om door te gaan.
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vrolijkheid leert me alles te relativeren, bedankt!
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